Host species-specific interactions of protein kinase R and poxvirus pseudosubstrate inhibitors by Peng, Chen
  
 
 
HOST SPECIES-SPECIFIC INTERACTIONS OF PROTEIN KINASE R AND POXVIRUS 
PSEUDOSUBSTRATE INHIBITORS 
 
 
by 
 
 
CHEN PENG 
 
 
 
B.E., Shenyang Pharmaceutical University, 2010 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Division of Biology 
College of Arts and Sciences 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2016 
 
 
  
  
Abstract 
Poxviruses are large double-stranded DNA viruses that collectively exhibit a broad host 
range. Whereas many members of the poxvirus family are capable of infecting various host 
species, others are restricted to only one or a very limited numbers of species, such as variola 
virus, which is the causative agent of smallpox and is restricted to humans. Since the entry of 
poxviruses is not dependent upon any specific receptors, the cell tropism is therefore fully 
determined by the virus’ ability to manipulate the cellular signaling networks that are responsible 
for antagonizing viral infections. Double-stranded RNA (dsRNA)-dependent protein kinase 
(PKR) is a unique antiviral protein found in most vertebrates, which serves both as a virus sensor 
by detecting the presence of dsRNA and an antiviral effector by suppressing cap-dependent 
translation during virus infection. Many viruses, including poxviruses, have therefore evolved 
genes that encode for PKR inhibitors, such as vaccinia virus K3L, which shows sequence 
homology to the N-terminal region of the eukaryotic translation initiation factor 2α (eIF2α), the 
substrate of PKR. K3L is able to inhibit PKR-mediated eIF2α phosphorylation in vitro and in 
vivo. Because K3L was shown to be indispensable for virus replication in Syrian hamster cells 
but not in human cells, it was categorized as a host range factor. However, the molecular basis 
for K3L’s host range function is not fully understood. We examined the interactions of poxvirus 
K3L orthologs, especially vaccinia virus K3L and M156R, the K3L ortholog in the rabbit-
specific myxoma virus, and PKR from a variety of host species in multiple assays, and found that 
K3L and M156R inhibit PKR in a species-specific manner, which likely contributes to the cell 
tropism and host range for both viruses. Inactivation of M156R or K3L led to virus attenuation in 
cells, which could be rescued by ectopic expression of viral PKR inhibitors. We also identified 
the helix αG region as the main molecular determinant for PKR’s sensitivity to inhibition by 
  
K3L orthologs. In conclusion, the research summarized here indicates that the interactions of 
PKR and poxvirus pseudosubstrate inhibitors play important roles in virus host range and 
virulence. 
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translation during virus infection. Many viruses, including poxviruses, have therefore evolved 
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homology to the N-terminal region of the eukaryotic translation initiation factor 2α (eIF2α), the 
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but not in human cells, it was categorized as a host range factor. However, the molecular basis 
for K3L’s host range function is not fully understood. We examined the interactions of poxvirus 
K3L orthologs, especially vaccinia virus K3L and M156R, the K3L ortholog in the rabbit-
specific myxoma virus, and PKR from a variety of host species in multiple assays, and found that 
K3L and M156R inhibit PKR in a species-specific manner, which likely contributes to the cell 
tropism and host range for both viruses. Inactivation of M156R or K3L led to virus attenuation in 
cells, which could be rescued by ectopic expression of viral PKR inhibitors. We also identified 
the helix αG region as the main molecular determinant for PKR’s sensitivity to inhibition by 
  
K3L orthologs. In conclusion, the research summarized here indicates that the interactions of 
PKR and poxvirus pseudosubstrate inhibitors play important roles in virus host range and 
virulence.
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Chapter 1 - Introduction 
Poxviruses 
 Phylogeny 
Poxviruses are large double-stranded DNA viruses whose replication is restricted to the 
cytoplasm of host cells (1). Poxviruses as a family, can infect almost all vertebrate species and 
many invertebrates (1). Poxviruses can be classified into two subfamilies: Chordopoxvirinae, 
whose members mainly infect vertebrate hosts, and Entomopoxvirinae, which includes 
poxviruses that are restricted to insect hosts. The subfamily Chordopoxvirinae is currently 
grouped in to ten genera: orthopoxviruses, yatapoxviruses, leporipoxviruses, capripoxviruses, 
cervidpoxviruses, suipoxviruses, parapoxviruses, molluscipoxviruses, crocodylipoxviruses and 
avipoxviruses (Figure 1.1). Among these ten genera, yatapoxviruses, leporipoxviruses, 
capripoxviruses, cervidpoxviruses and suipoxviruses can be classified as “clade II poxviruses 
due to the fact that they form a sister-clade to orthopoxviruses in phylogenetic trees (Fig. 1.1) (1-
3).   
Two of the best known members of all poxviruses are variola virus, the causative agent of 
smallpox, which caused more human fatalities than all other infectious diseases combined, and 
vaccinia virus, which is often considered the prototypic poxvirus. The studies presented in this 
dissertation will be focused on vaccinia virus and myxoma virus, a member of the leporipoxvirus 
genus.  
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 Vaccinia virus 
Vaccinia virus is the most extensively studied poxvirus. Historically, vaccinia virus was 
the first animal virus observed microscopically, replicated and titered successfully in tissue 
culture, physically purified and biochemically characterized. Vaccinia virus was used in the 
vaccination campaign against smallpox led by the World Health Organization, which eventually 
led to the eradication of smallpox in 1977 (4, 5). The study of vaccinia virus also contributed 
largely to the advancement of many aspects of biological research. For example, the discovery of 
RNA polymerase in purified vaccinia virus virions revised an once universal perception that 
virus particles are simply packets of nucleic acids without any protein products (6). Vaccinia 
virus has also been extensively used as an expression vector for various purposes such as vaccine 
development and cancer treatment due to the relative ease of generating and isolating 
recombinant viruses, and due to its genetic capacity for taking large amounts of foreign DNA 
(7).   
The precise origin and the natural host(s) of vaccinia virus is/are unknown. The current 
strains of vaccinia virus have been repeatedly passaged in cultured cells and animals for many 
decades (1). Experimentally, vaccinia virus displays a broad host range. Many vaccinia virus 
strains are able to establish infections experimentally in primates, rodents, lagomorphs and 
ungulates (1). Some variants of vaccinia virus have also been identified such as buffalopox, 
which probably represent a vaccinia virus strain that escaped during the vaccination campaign 
(1). Vaccinia virus usually causes mild infections in humans. But the virus can cause serious 
illness, even death, in immunocompromised individuals. In addition, vaccinia virus that is 
maternally passed to the fetus can cause lethal infections (1).   
3 
Like all poxviruses, vaccinia virus encodes a large pool of proteins aimed to modulate the 
host’s antiviral immune responses to benefit the survival and replication of the virus. These 
genes are collectively termed immunomodulatory genes. The protein products of these genes 
often interact with one or multiple host factors that are involved in antiviral immune responses. 
Protein products of the vaccinia virus immunomodulatory genes function by modulating 
different aspects of the antiviral responses of the host. Examples of targets include the 
complement regulatory proteins, interferon-binding proteins, interleukin-18-binding proteins, 
soluble tumor necrosis factor-binding proteins, NF-κB-binding proteins, inhibitors of apoptosis, 
etc (reviewed in (8)). Some vaccinia virus genes were found to be indispensable for virus 
replication in cell lines derived from certain species, but not in the others, such as E3L and K3L, 
and are hence termed host range genes (1). Vaccinia virus E3L and K3L are both inhibitors of 
the host’s antiviral protein kinase R (PKR). The detailed mechanism of PKR inhibition by K3L 
and E3L will be discussed later in this chapter.  
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 Myxoma virus  
 Myxomatosis  
Myxoma virus is a member of the genus leporipoxvirus. Infections that are caused by 
myxoma virus and rabbit fibroma virus, two members of this genus, are strictly restricted to 
animals of the leporidae family, which include rabbit and hare species. Myxoma virus infection 
was first documented in Uruguay, in 1896, where an outbreak of a novel lethal disease in 
laboratory-raised European rabbits, later termed myxomatosis, was observed (9). In 1898, the 
disease was suggested to be caused by a viral pathogen, which made myxomatosis one of the 
earliest described animal diseases to be associated with a virus. Thirty years after the initial 
documentation of the virus in South America, myxomatosis was observed for the first time in 
North America (9, 10).  
Myxoma virus is extremely virulent in European rabbits, causing a mortality rate close to 
100% (reviewed in (11)). Clinical signs of myxomatosis, including conjunctivitis, elevated 
temperature and raised cutaneous lesions can be observed as early as 4 days post infection. At 8-
10 days after infection, animals usually begin to develop more severe symptoms such as swollen 
head, drooping ears, closed eyelids and mucopurulent rhinitis. In male animals, extreme swelling 
of the scrotum and testes can also be observed at this stage. Death caused by myxomatosis often 
occurs 8 to 12 days post infection (11, 12). The virus found in secretions and in skin lesions can 
be transmitted by direct contacts or by biting arthropod vectors such as mosquitos and fleas to 
naïve animals (13, 14).  
The natural hosts of myxoma virus are Sylvilagus leporids including the South American 
tapeti rabbit (Sylvilagus brasiliensis) and the North American brush rabbit (Sylvilagus bachmani) 
(15). Interestingly, in contrast to the lethal disease myxomatosis caused by myxoma virus in 
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European rabbits, the virus only causes mild symptoms in its natural hosts, including innocuous 
cutaneous fibromas, which are often restricted to the site of inoculation. Death is often not 
observed unless in very young rabbits (9, 15).  
 Immune responses to myxoma virus infection  
Rabbits infected with myxoma virus can develop IgG and IgM antibodies in serum to 
levels that are quantifiable by ELISA or neutralization assays as early as six days post infection 
(12, 16). Antibodies produced in serum remain detectable for as long as two years in wild rabbits 
that were naturally infected (17). These IgG antibodies can also cross the placenta, and can be 
found in kittens until 6 weeks after birth (18). However, it remains inconclusive whether 
maternal antibodies provide sufficient protection from natural infection (19). Besides antibody 
mediated immunity, cell mediated immunity also plays an important role in clearing the poxvirus 
infection and preventing reinfection. During myxoma virus infection, cell mediated immunity 
constitutes dendritic cell activation and the production of appropriate cytokines to activate Th1 
skewed CD4+ T cells (20, 21). In experimental settings, rabbits that have recovered from 
myxomatosis naturally do not develop myxomatosis even with high doses of virus challenge, but 
they do initiate a localized immune reaction at the site of inoculation, indicating the involvement 
of cell mediated immunity in response to reinfection of myxoma virus (19, 22).  
 Genome structure of myxoma virus 
Like all poxviruses, the myxoma virus genome is composed of linear double-stranded 
DNA. The genes in the myxoma virus genome are tightly compact and efficiently organized 
(23). The Lausanne (Lu) strain, which is often considered to be the reference myxoma virus 
strain, contains 161,774 base pairs (bp) with a A/T content of 56.4% (23). A total of 171 
complete open reading frames have been annotated in the genome. The myxoma virus Lu 
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genome, like other poxvirus genomes, contains terminal inverted repeats (TIR) that are 11.5 kb 
in length. The boundaries between TIRs and the central core sequences lie between the 
M008.1L/R and the M009L/M156R genes. The central core of the genome, which is relatively 
conserved across all poxviruses, constitutes of genes that are essential for virus replication such 
as those that encode for transcriptional machinery or structural components of the virion. The 
immunomodulatory genes and/or host range factors, on the other hand, are more often localized 
toward the ends of the genome, especially in the TIR regions (23).  
Myxoma virus promoters, like all poxvirus promoters, are classified into three categories: 
Early, intermediate and late. All promoter sequences found in myxoma virus contain core 
elements that are found in other leporipoxviruses and are also conserved among all 
orthopoxviruses (23).  
In addition to the Lu strain, the genome of a myxoma virus MSW strain, which naturally 
infects brush rabbits (Sylvilagus bachmani) was also fully sequenced and published (24). The 
MSW genome is slightly larger than that of the Lu strain of MYXV, containing 164,600 bp of 
dsDNA, due to an expanded TIR. Five complete genes, including M156R, M154L, M153R, 
M152R, and M151R as well as part of M150R are duplicated in the TIR. Compared to the 
genome of the Lu strain, no novel genes were found, but five genes were found to be disrupted 
due to mutations, insertions or deletions. The MSW strain exhibits higher virulence than the Lu 
strain in European rabbits, indicated by their ability to kill infected European rabbits more 
rapidly (25). European rabbits infected with the MSW strain of MYXV usually die within 10 
days without showing clinical signs of myxomatosis. Importantly, in contrast to the Lu strain, the 
MSW strain of MYXV caused 100% mortality in wild rabbits that are genetically resistant to the 
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Lu strain of MYXV. Unfortunately, it is not immediately clear which gene(s) are responsible for 
the difference in virulence between the Lu strain and the MSW strain (25).  
Replication cycle  
All poxviruses replicate exclusively in the cytoplasm of infected cells (reviewed in (26)). 
Two types of mature virions are generated during a replication cycle and can initiate new 
infections; the intracellular mature virus and the extracellular enveloped virus (27). The entry of 
myxoma virus does not require any specific receptors on the surface of the host cell (6, 28). 
Myxoma virus particles can attach to target cells by membrane fusion, or by the process of 
endocytosis (29). A permissive infection is defined by the completion of three stages of viral 
transcriptions and translations, known as early, intermediate and late stages (26). The initiation 
of intermediate and late transcription requires the completion of the early and intermediate 
protein synthesis, respectively (26). The newly packaged virus particle is transported through 
microtubules and is wrapped with membranes derived from the Golgi to form the intracellular 
enveloped virus, which can either stay in the infected cells as an intracellular mature virus or be 
released to form the extracellular enveloped virus. Extracellular mature viruses are free virus 
particles that can initiate new infections by attaching to naïve uninfected cells, while the release 
of intracellular mature virus requires cell lysis (6, 30, 31).  
 Myxoma virus immunomodulatory proteins 
Like many large DNA viruses, myxoma virus encodes a large number of genes, whose 
protein products are specialized to manipulate or evade the host antiviral immune responses in 
order to establish successful replication. These proteins target different pathways of the host 
immune responses to favor virus replication, and are therefore collectively termed viral 
immunomodulatory factors (reviewed in (32-34)). Based on their subcellular localization during 
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an infection, myxoma virus immunomodulatory factors can be categorized into two groups. 
“Viromimetics” are those that are usually secreted or cell surface-bound, which mainly mimic 
the host immune factors to disrupt their functions (35). Members of the other group, named 
“virostealth”, however, remain intracellular to prevent infected cells from entering apoptosis or 
keep the virus from being recognized by the immune system (35). The viral immunomodulatory 
proteins can also be grouped based on their mode of action. Viroreceptors mimic cytokine 
receptors to disrupt the action of cytokines. For example, myxoma virus M-T7, a homolog of the 
interferon-γ receptor, is secreted during virus infection to sequester free interferon-γ (36, 37). 
Viromitigators are those that stay intracellularly and disturb specific signal transduction cascades 
that are critical for the regulation of antiviral activities (35). A well-studied example of 
viromitigators is the myxoma virus M-T5, an ankyrin-repeat protein that interrupts pathways 
mediated by Akt and cullin-1 through direct binding (38). Moreover, myxoma virus also 
possesses genes that encode proteins aimed to terminate the cascade of apoptosis such as SERP-
2, M11L, M-T2, M-T4 and M-T5 (38-42). In addition, many myxoma virus immunomodulatory 
proteins are multifunctional. For example, M-T7 was shown to be able to inhibit interferon-γ and 
to interact with heparin binding proteins such as chemokines (43). Recently, another dual 
function immunomodulatory protein, M029, was identified, which was able to both inhibit the 
antiviral kinase protein kinase, PKR and conscript RHA/DHX9 to promote viral replication and 
expand the host tropism (44). 
 Myxoma virus host range factors 
As a family, poxviruses can infect a variety of animal species, including insects, birds 
and mammals. However, the host range of each individual poxvirus varies tremendously even 
between very closely related strains. For instance, variola virus, the causative agent of smallpox 
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evolved as a human-specific pathogen. Others, such as cowpox virus, in contrast, an 
orthopoxvirus closely related orthopoxvirus to variola virus, is known to infect more than three 
hundred different species (6). The difference in host range sizes among poxviruses is believed to 
be caused by viral proteins that influence virus host ranges, termed host range factors. Myxoma 
virus infection is restricted to rabbits and hares, making it a great model organism to study viral 
host range factors and their interactions with the host’s antiviral proteins. However, the 
molecular mechanisms by which myxoma virus displays such a narrow host range remain 
unknown. Recently, several host range proteins have been identified and characterized in 
myxoma virus. A myxoma virus lacking M062R was shown to cause abortive replication in 
rabbit cells and asymptomatic infections in European rabbits (45). In addition, a binding partner 
of M062, named sterile alpha motif domain 9 (SAMD9), was identified in human cells, and was 
convincingly shown to be responsible for the blockage of M062R-deficient myxoma virus in 
human cells (45). However, the rabbit homologue of SAMD9 was not characterized and it is 
therefore unknown if M062R functions in a species-specific manner (46). Moreover, a mutant 
strain deficient for M063R was able to replicate to similar levels as the wild type virus in 
monkey BGMK cells but failed to replicate in rabbit RK13 cells and was not able to cause 
myxomatosis in European rabbits (47). In addition, myxoma virus M064R is another gene 
closely related to M062R and M063R, however, in contrast to the latter two, M064R functions 
solely as a virulence factor and lacks the host range functional properties of M062R and M063R 
(48). Another interesting example of a myxoma virus host range factor is M-T2, which is a dual 
function inhibitor of the host tumor necrosis factor alpha. M-T2 has two activities; 1) the 
secreted protein binds and inhibits extracellular tumor necrosis factor alpha, and 2) the same 
protein also localizes to the cell surface where it binds and inhibits cellular tumor necrosis factor 
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receptor alpha receptor. The first activity is rabbit-specific while the second one is not (41, 49-
51).  
Importantly, all myxoma virus immunomodulatory proteins and host range factors 
evolved in the natural hosts of myxoma virus: Sylvilagus rabbits, such as the brush rabbit or 
tapeti rabbit. However, studies on their functions were performed mostly in laboratory rabbits, 
which are derived from European rabbits (Oryctolagus cuniculus). Therefore, it is possible that 
some host species-specific interactions are neglected and some identified functions might be the 
consequences of off-target interactions between myxoma virus proteins and the host antiviral 
factors from Oryctolagus rabbits.  
 Evolution of myxoma virus in Australia and Europe 
Myxoma virus naturally infects North American brush (Sylvilagus bachmani) and South 
American tapeti (Sylvilagus brasiliensis) rabbits. In 1950, myxoma virus was introduced into 
Australia as a biological control of invasive feral European rabbits, which caused tremendous 
economic and ecological havoc. Because European rabbits had never naturally encountered the 
virus before its deliberate release, the evolution of myxoma virus in Australia became one of the 
best examples to study how a virus evolves to adapt to a new host species and how the host co-
evolves simultaneously. The virus initially released in Australia was termed the standard 
laboratory strain (SLS), which was isolated from a European rabbit in Brazil and passaged many 
times in laboratory European rabbits (52).  
Based on the fatality rate and the clinical symptoms it causes, myxoma virus can be 
categorized into 5 levels of virulence. The SLS strain is of grade 1 virulence, causing a case 
fatality rate of 99.8% in laboratory European rabbits (22). After its initial release, the virus began 
to become attenuated and soon, viruses of grade 3 and 4 virulence with 70-95% case fatality rate 
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started to dominate the field despite the regular and repeated release of grade 1 viruses into the 
field (12, 53). The grade 1 virus could be isolated in the field only within 6 months of the release 
in a given area, indicating the extremely fast pace of virus evolution (54).  
In addition to the attenuation of the virus, wild rabbits also became more resistant to 
myxoma virus infection. The quick emergence of more attenuated myxoma virus strains 
provided opportunities for rabbits with certain levels of genetic resistance to survive. In one 
study, rabbit kittens from the area around Lake Urana captured in the field were housed and 
raised in laboratory settings and challenged with a grade 3 strain (KM13) of virus to monitor 
their responses. The percentage that died from myxomatosis dropped from above 80% in 1953 to 
around 30% in 1958, suggesting that quick selection of resistant animals in this area occurred 
(55-57).  
A similar trajectory of virus-host coevolution was observed in Europe. Two years after 
the release of MYXV in Australia, the virus was illegally introduced into Maillebois, a commune 
70 km west of Paris. The released virus was a more virulent strain than the SLS, and was derived 
from a laboratory in Lausanne, Switzerland, hence it was named the Lausanne strain. The virus 
soon spread throughout Europe and Britain, causing ecological problems and economical loss in 
the rabbit farming industry until it was controlled by mass vaccination and an enforced 
quarantine (58). It was estimated that the rabbit population in France dropped by 90-98% due to 
the spread of myxoma virus (14). The evolution of myxoma virus in Europe was very similar to 
that in Australia. Grade 3 and 4 viruses were isolated from the field in France three years after 
the initial release, and grade 3 viruses became the predominant isolates in both Britain and 
France (12, 59). The common evolutionary trajectory of myxoma virus in Australia and Europe 
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suggests a possibility that common mechanisms were involved in virus evolution on two 
continents, especially the evolution of virus attenuation.  
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Type I interferon-mediated antiviral responses  
 Interferons  
Interferons are a group of cytokines found in jawed vertebrates that mediate potent 
antiviral and anti-proliferative effects (60). Interferons are one of the earliest lines of protection 
for the host in response to virus infection. The finding that all vertebrates characterized to date 
have genes encoding members of the interferon family and the high conservation of interferons 
suggests their importance for the immune response against pathogens. Interferons are named 
after their ability to interfere with viral infection. In addition to its involvement in antiviral 
immunity, interferons also play roles in activating natural killer cells and macrophages, up-
regulating antigen presentation and are responsible for inducing infection-related symptoms in 
organisms such as fever and muscle pain (61).  
The interferon family can be grouped into two major categories: Type I and type II 
interferons. Type I interferons share considerable structural homology and can be further 
classified into two major groups: Interferon α and interferon β. Type II interferon includes only 
one member, interferon γ, which differs dramatically from type I interferons in mode of action, 
aspects of the receptors and structure and will not be discussed in depth in this dissertation.  
 Type I interferon-mediated antiviral signaling pathways 
Human interferon α can be divided into thirteen subtypes, including interferon α1, α2, 
α4, α5, α6, α7, α8, α10, α13, α14, α16, α17, α21 (61). The genes encoding type I interferons 
are all localized and clustered on chromosome nine in humans (62). Both interferon α and β bind 
to common receptors localized on the surface of most cells called type I interferon receptors 
(reviewed in (63)). The binding of interferons to their receptors can trigger a series of antiviral 
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immune reactions by inducing the expression of hundred of genes that act to antagonize virus 
infections (64). 
Production of interferons can be triggered by the activation of two major types of viral 
sensors: Toll-like receptors which are localized on the cell surface or in endosomes; and 
intracellular cytosolic nucleic acid receptors, which together are collectively termed pattern 
recognition receptors (65, 66). These pattern recognition receptors work as sentinels in cells to 
detect the presence of foreign nucleic acids including DNA and RNA and subsequently initiate 
immune responses upon activation. Toll-like receptors are primarily expressed in immune cells 
such as dendritic cells and macrophages, while cytosolic receptors are found in almost all cell 
types (67).  
When a host cell is invaded by a virus, cytosolic receptors such as RIG-I (retinoic acid-
inducible gene 1) and MDA-5 (melanoma Differentiation-Associated protein 5) are activated, 
which subsequently activate interferon-regulatory factors (IRFs) and NF-κB (68). The latter two 
function as transcription factors and translocate into the nucleus to induce the expression of type 
I interferons, which are then secreted and induce an interferon-mediated immune response in a 
paracrine or autocrine manner. This induces the expression and activation of interferon 
stimulated genes in the infected cell and in surrounding cells to fight viral infections (Fig. 1.2) 
(68). 
 The double-stranded RNA-dependent protein kinase   
The genes that are up-regulated by type I interferons are called interferon stimulated 
genes (ISGs) (64). Among them, the double-stranded RNA-dependent protein kinase (PKR) is 
unique, because it functions as both a pattern recognition receptor that senses viral invasion and 
an interferon-induced antiviral effector that suppresses viral replication. PKR is found in bony 
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fish, amphibians, reptiles and mammals, suggesting an important role in the defense against viral 
infections over the course of vertebrate evolution. The following entails a detailed descriptions of 
PKR’s enzymatic activity and its role in antiviral immune responses.  
 Activation and activity 
PKR is a protein found in vertebrates and is known as an antiviral protein kinase. PKR is 
composed of two N-terminal double-stranded RNA binding domains that bind double-stranded 
(ds) RNA, a linker region and a C-terminal kinase domain that categorizes it as a member of the 
family eukaryotic translation initiation factor 2 α (eIF2α) kinase family. In unstimulated cells, 
PKR is expressed at intermediatel levels and remains in a latent monomeric form (69, 70). 
Traditional activation of PKR requires the presence of dsRNA produced during viral replication. 
Binding of dsRNA to the dsRNA binding domains of PKR triggers conformational 
rearrangements of the molecule, which bring two monomers into close proximity to form dimers 
(71). Activation of PKR needs a minimum of 30 base pairs of dsRNA and the optimal activation 
requires double-stranded RNA that is longer than 80 base pairs (72, 73). The activation is 
sequence-independent, allowing PKR to be activated by RNA of a variety sources (73). In 
addition to double-stranded RNA, a human protein named PACT (PKR activating protein), and 
its mouse homolog RAX (PKR associated protein X) have also been identified as internal PKR 
activators in response to cellular stress such as serum starvation, peroxide or arsenite treatment 
(74-77).  
Upon activation, PKR molecules dimerize and the concomitant autophosphorylation 
occurs on the threonine residue 446 in human PKR (78, 79). The active dimer subsequently 
phosphorylates the residue serine 51 in eIF2α (80). Phosphorylated eIF2α then competitively 
inhibits the recycling of the GDP-bound form of eIF2 to the GTP-bound form by eIF2B, which is 
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a guanine exchange factor for eIF2α that is present only in limited amounts. Cap-dependent 
translation then halts because eIF2α can no longer be recycled for re-initiation of translation 
(reviewed in (81)). Because cap-dependent viruses rely on the host translational machineries for 
the translation of viral proteins, replications of these viruses are therefore repressed when the 
host translation is blocked by phosphorylation of eIF2α by active PKR (82).  
 Inhibition of PKR by viruses 
PKR activation is an important process in the antiviral immune response due to its special 
role as both a virus sensor and an antiviral effector. Therefore, many viruses have evolved genes, 
whose protein products aim to directly target PKR, or to sequester dsRNA, to subvert the 
antiviral immune responses mediated by PKR (83). The mode of action of viral PKR inhibitors 
varies dramatically from virus to virus but almost every single step of PKR activation and 
activity has been targeted by at least one viral antagonist (83). For example, vaccinia virus E3, 
influenza virus NS1 and herpes virus US11 inhibit PKR by binding dsRNA and thereby 
preventing PKR dimerization (84-86). Vaccinia virus K3L and human immunodeficiency virus 
tat compete with eIF2α for PKR binding (87, 88). Apart from directly inhibiting PKR, some 
other viral products such as herpes virus γ34.5 can alleviate PKR-mediated translational 
suppression by inducing dephosphorylation of eIF2α, the substrate of PKR (89, 90). Overall, the 
PKR-mediated antiviral response constitutes one of the earliest obstacles that viruses have to 
overcome in order to establish successful replication in vertebrates. 
Fast evolution of PKR 
In addition to PKR, four other eIF2α kinases have been recognized in higher eukaryotes 
that can regulate translation (reviewed in 81) (Fig. 1.3). Members of the eIF2α kinase family all 
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contain homologous kinase domains, but possess different regulatory domains, which can detect 
and be activated by different stress signals (91). PKR differs from other eIF2α kinases due to its 
unique evolutionary trajectory. Specifically, PKR faces the challenges to not only maintain its 
ability to bind and phosphorylate eIF2α, a highly conserved protein, but also simultaneously 
evade inhibition by viral eIF2α homologues such as vaccinia virus K3L. A recent study of our 
lab examined the evolutionary pattern of the kinase domain of PKR and found that PKR has 
evolved much faster than the other eIF2α kinases PERK (PKR-like endoplasmic reticulum 
kinase), HRI (heme-regulated inhibitor kinase) and GCN2 (general control nonderepressible 2). 
Moreover, 35 sites in the kinase domain were identified to have been under positive selection, 
and the mutation of more than half of these residues altered the sensitivity of human PKR to 
vaccinia virus K3L (92). A related study published at the same time focused on primate PKRs 
revealed a similar pattern supporting the rapid evolution of PKR (93). In addition to PKR, this 
study also showed that residues in vaccinia virus K3L are also under strong positive selection as 
a result of the counteracting adaptive changes in the kinase domain of PKR. In contrast to PKR, 
eIF2α is highly conserved across species and over the course of evolution. All these studies 
suggest that the molecular arms-race between PKR and its viral antagonists likely drive the fast 
evolution of both. 
  
18 
 
 
 
 
Figure 1.1 Phylogeny of poxviruses 
 
Phylogenetic tree of fully sequenced poxviruses adapted from Haller et al. (1).  
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Figure 1.2 Type I interferon-mediated antiviral pathways 
 
Upon virus infection, double-stranded RNA (purple) is detected by pattern recognition 
receptors, which subsequently upregulate type I interferons (IFNs, light green). IFNs are secreted 
and trigger upregulation of interferon stimulated genes (ISGs) including PKR by binding to IFN 
receptors (IFNR, dark green), which activates the JAK-STAT pathway, to fight against viral 
infection. Double-stranded RNA can be directly detected by PKR, which is required for PKR 
dimerization and activation.  
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Figure 1.3 Domain organization of eIF2α kinases 
 
Abbreviations: HBD: heme binding domain; dsRBD: double-stranded RNA binding 
domain; TM: transmembrane; RWD: RING finger-containing proteins, WD-repeat-containing 
proteins; HisRS; Histidyl-tRNA synthetase; ZBD: Z-DNA binding domain 
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Chapter 2 - Characterization of the host range function of K3L and 
selected K3L orthologs 
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 Abstract 
Poxviruses exhibit wide variation in host range. For example, vaccinia virus (VACV), 
which was used for the vaccination against smallpox, has a very broad host range and is able to 
infect many different species. In contrast, others such as swinepox virus, which only infects pigs, 
display a very narrow host range. However, the molecular mechanisms controlling the 
differences in poxvirus host range are unknown. Since the entry of poxviruses into a host cell is 
species-independent, the host range of any given poxvirus is determined by its ability to subvert 
the host’s antiviral immune responses, in which an important step constitutes the inhibition of the 
antiviral factor protein kinase R (PKR). PKR suppresses general translation during virus 
infection and has evolved rapidly in vertebrates, which was likely caused by the selective 
pressure exerted by several viral inhibitors. VACV encodes the two PKR inhibitors E3L and 
K3L, both of which are host range genes for the virus. Whereas K3L was shown to be necessary 
for VACV replication in Syrian hamster BHK21 cells, E3L was essential for replication in cells 
from other species such as human HeLa cells. To determine the molecular basis for this host 
range function of K3L and E3L, we used a luciferase reporter transfection assay in PKR-
deficient HeLa cells to measure interactions between these inhibitors and PKR from a variety of 
mammalian species. Our results show a surprising variation in the sensitivity of PKR to VACV 
inhibitors, especially K3L, and its orthologs from sixteen other poxviruses. We found that the 
sensitivity of each species’ PKR to E3L or K3L correlated with virus replication and the 
phosphorylation of eIF2α in cell lines derived from the respective species after infection with 
VACV mutants that lack E3L, K3L or both. Our results show that the host range function of K3L 
can be explained by species-specific differences in the sensitivity of PKR to these VACV 
inhibitors. We also found that a K3L ortholog from swinepox virus inhibited only swine PKR but 
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not PKR from other species tested, which might contribute to the species-specificity of swinepox 
virus.  
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 Introduction 
VACV is a prototypic poxvirus that belongs to the genus orthopoxvirus. VACV is the 
most intensively studied poxvirus and is well-known for its use as a vaccine strain in the global 
campaign to eradicate smallpox (reviewed in (1)). Due to its large genetic encoding capacity and 
the feasibility of genetic manipulation, VACV has also been widely used as a vector for vaccine 
development (reviewed in (2, 3)). The current strains of VACV used in laboratories have 
undergone untraceable propagations in animals and cell lines for decades. The origin, and most 
importantly, the natural host of VACV, is therefore unknown. In experimental settings, VACV 
displays a broad host range in animals, productively infecting humans, rodents, lagomorphs and 
ungulates (reviewed in (4, 5)). In addition, VACV can infect cell lines derived from a variety of 
species (4). However, the molecular mechanisms for the cellular tropism and host specificity of 
VACV remain unclear. Some poxvirus genes are found to be dispensable for virus replication in 
cell lines derived from certain species, but are important in others. These genes are therefore 
termed host range genes. These host range genes directly influence the host range and potentially 
virulence of poxviruses, because the entry of poxviruses is species-independent, the host range of 
a particular virus is dependent on its ability to subvert the host innate immune response (4). The 
protein products of host range genes often target one or multiple pathways associated with the 
host’s antiviral immune response.  
One most important group of poxvirus host range genes comprise PKR inhibitors. VACV 
possesses the PKR inhibitors E3L and K3L, which antagonize the PKR-mediated antiviral 
response at different steps (6). E3L and K3L gene orthologs are found in many poxviruses, 
indicating the importance of PKR inhibition for poxvirus replication (7). VACV E3L contains an 
N-terminal Z-DNA binding domain and a C-terminal dsRNA binding domain. Whereas only the 
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dsRNA binding domain is required for virus replication in cells, both domains are indispensable 
for VACV pathogenesis in mice (8, 9). It is generally acknowledged that E3L inhibits PKR by 
binding dsRNA molecules produced during virus infection, and thereby prevents PKR activation. 
However, a recent study challenged this perception by showing that the biological function of 
E3L does not fully rely on its capability to bind double-stranded RNA (10). The study also 
showed evidence that E3L was able to be co-immunoprecipated with PKR during infection, 
suggesting E3L may exert its host range function through mechanisms other than double-
stranded RNA sequestration (10). However, the extent to which the PKR-E3L interaction 
contributes to the biological function of E3L remains unknown.  
VACV K3L, on the other hand, is a homologue of eIF2α, the substrate of PKR, and 
functions as a pseudosubstrate inhibitor by binding to eIF2α binding site on the kinase domain of 
PKR and therefore excluding eIF2α (11-14). Interestingly, deletion of K3L diminished the 
replication of VACV in Syrian hamster BHK21 and murine L929 cells but not in human HeLa 
cells, which categorized K3L as a host range gene of VACV (6). Orthologs of VACV K3L are 
found in most orthopoxviruses and all clade II poxviruses (7). Their sequences, however, are 
highly divergent compared to that of other poxvirus genes. In fact, K3L orthologs from different 
poxviruses can display as low as 25% sequence identity with each other (7). One explanation for 
this is that since K3L orthologs from different poxviruses evolved in different animal reservoirs, 
the evolutionary pressure exerted by the host’s antiviral immune response may have driven the 
K3L orthologs to evolve to optimize their activity in the natural host of each virus. Interestingly, 
Elde et al. found that under an experimentally induced selective pressure, in which E3L is 
deleted from VACV, the remaining PKR inhibitor K3L could quickly evolve to evade the 
antiviral effects imposed by PKR through an accordion-like expansion of the K3L gene locus. 
33 
The quick amplification of K3L copy number allows for more efficient accumulation of 
mutations, which facilitated the selection of mutations that have improved PKR inhibitory 
capability (15). The result of this experimentally accelerated virus evolution can possibly explain 
how K3L and its orthologs evolved in different animal hosts, which ultimately causing their 
divergence.  
As a result of the selective pressure exerted by highly divergent K3L orthologs, PKR 
from different species also exhibit high levels of variation (16). Notably, we and others showed 
that the high degree of diversity in the kinase domain of PKR resulted in varied levels of 
sensitivity displayed by different species’ PKR to VACV K3L. For example, whereas human 
PKR was largely resistant to K3L inhibition, mouse PKR was very sensitive (16). Moreover, 
PKR from hominoid primates were more resistant to K3L inhibition than those from old or new 
world monkeys (17). The species-specific inhibition of PKR by K3L was observed in a variety of 
assay systems, however, the extent to which it contributes directly to the host range function of 
K3L and how it influences the host range of VACV have not been studied.  
In this chapter, we thoroughly examined the inhibitory effect of VACV K3L and its 
poxvirus orthologs from 16 different poxviruses on PKR from various mammalian species using 
a previously described transfection assay (16). We also investigated how the inhibition of host 
PKR by K3L contributes to the cellular tropism of VACV and the PKR-mediated antiviral 
response in cell lines derived from different species. In addition to VACV K3L, we also 
analyzed a K3L ortholog from swinepox virus named C8L, and found that it evolved to 
specifically inhibit swine PKR with the highest efficiency. The host species-specific inhibition of 
swine PKR by C8L may therefore contribute to the limited host range displayed by the swinepox 
virus.   
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Materials and Methods 
 Plasmids, cell lines and viruses 
PKR and viral genes were cloned into the pSG5 vector (Stratagene) for transient 
expression in mammalian cells. Cloning of European rabbit PKR, brush rabbit PKR, Eastern 
cottontail PKR, Sheep PKR, rat PKR, Syrian hamster PKR, Chinese hamster PKR and Guinea 
pig PKR was described in detail in Chapter 3. Cloning of knock-down resistant human PKR and 
mouse PKR was described previously (16). Chimpanzee PKR, orangutan PKR, gibbon PKR, 
macaque PKR and tamarin PKR were kindly provided by Nels Elde. Turkish hamster PKR was 
cloned from cDNA generated from testicular total RNA from a Turkish hamster. Armenian 
hamster PKR was cloned from the total RNA collected from AHL-1 cells. Cat PKR was cloned 
from CRFK cells (ATCC-CCL94) and was identical to XP_003984379.1. Dog PKR was cloned 
from MDCK cells (ATCC-CCL34). Three identical cDNA clones contained the same amino-acid 
difference from NP_001041600.1. Horse PKR was cloned from horse cells (efc cells, kindly 
provided by Udeni Balasuriva and Ying Fang) and was identical to XP_008514381.1. Cow PKR 
was cloned from cow cells MDBK cells (ATCC-CRL6071) and was identical to NP_835210.2. 
Camel PKR was cloned from camel Dubca cells (ATCC-CRL2276) and was identical to 
XP_006192853.1. Pig PKR was cloned from swine PK-15 cells. VACV K3L (Copenhagen 
strain) and swinepox virus C8L were cloned into pSG5. All open reading frames were sequenced 
to confirm correct sequences. 
PKRkd HeLa cells and control HeLa cells were kindly provided by Charles Samuel (19). 
RK13 and PK-15 cells were kindly provided by Bernard Moss. Generation of RK13 cells with 
ectopic expression of E3 and K3 was described (20). CRFK cells, MDBK cells, PK-15 cells and 
rat-1 cells were obtained from ATCC. All cell lines were maintained in DMEM (Gibco) 
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supplemented with 5% FBS and 50µg/ml gentamycin at 37˚C with 5% CO2. For transfection 
assays, plasmids were prepared using the NucleoBond Xtra Midi Endotoxin Free plasmid 
preparation kit (Macherey-Nagel). 
The Copenhagen VC-2 and vp872 (K3L-deficient) VACV strains were kindly provided 
by Bernard Moss. The construction of VC-R1 (E3L-deficient), vp872 (K3L-deficient) and VC-
R2 (E3L-deficient, K3L-deficient) was described previously in (18). All virus strains used were 
amplified in PKRkd HeLa cells and purified by sucrose-gradient ultracentrifugation with the 
protocol described in (21).  
 Luciferase assay 
5 x104 HeLa-PKRkd cells were seeded in 24-well plates one day before transfection. For 
each transfection, firefly luciferase (pGL3promoter, 50 ng, Promega), and pSG5 plasmids 
encoding PKR (200 ng), VACV K3L, VACV E3L or swinepox virus C8L (400 ng) were 
transfected using GenJet-HeLa. For controls, empty pSG5 vector was transfected using the same 
amount. Each transfection was conducted in triplicate. After 48 hours, cell lysates were harvested 
using mammalian lysis buffer (Goldbio) and luciferase activity was determined using luciferase 
detection reagents (Promega) in a luminometer (Berthold). Each experiment was performed at 
least three times and representative experiments are shown in the results. Error bars represent the 
standard deviations of three replicate transfections. 
 Western blot analyses and Infection assays 
Different cell lines indicated in the figures were infected with VC-2, vp872, VC-R1 and 
VC-R2 at an MOI of 5 for 1 hour. Total protein was collected 6 hours after infection with 1%-
SDS in PBS. Protein samples were separated on 10% SDS-PAGE gels and transferred to PVDF 
membranes (GE Healthcare) using a methanol-based wet transfer apparatus (BioRad). 
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Membranes were blocked with 5% non-fat milk or 5% BSA when detecting eIF2α-P in TBST 
buffer (20mM Tris, 150mM NaCl and 0.1% Tween-20 pH7.6) for 3 hours at 4˚C with agitation 
and then incubated overnight with the rabbit anti-serum raised against eIF2α-P (Biosource 
International) at 4˚C with rocking, and then stripped and re-probed with antibody against total 
eIF2α (SantaCruz). After washing, membranes were incubated with goat-anti-rabbit or goat-anti-
mouse secondary antibodies (1:30,000) in TBST containing 5% non-fat milk for 1 hour at room 
temperature with agitation followed by TBST washing 4 times at 20 minutes each. Proteins were 
detected with Proto-Glo ECL (National Diagnostics) and images were taken with a Kodak image 
system. 
To determine virus titers, cell lines were infected with VC-2, VC-R1, vp872 and VC-R2 
at an MOI of 0.01. Viruses were collected 48 hours after infection by repeated freeze-thaw 
cycles and tittered on monolayers of RK13+E3L+K3L cells (20). Infections were performed in 
duplicates. Error bars indicate standard deviation. 
To examine the expression of K3L and K3L orthologs, human HeLa-PKRkd cells were 
transfected transiently with FLAG-tagged K3L orthologs. Protein lysates were collected 48 hours 
after transfection with 1%SDS-PBS. Total protein was collected 6 hours after infection with 1%-
SDS in PBS. Protein samples were separated on 12% SDS-PAGE gels and transferred to PVDF 
membranes (GE Healthcare) using a methanol-based wet transfer apparatus (BioRad). 
Membranes were blocked with 5% non-fat milk in TBST for 3 hours at 4˚C with agitation and 
then incubated overnight with the rabbit anti-FLAG antibody at 4˚C with rocking, and then 
stripped and re-probed with antibody against β-actin. After washing, membranes were incubated 
with goat-anti-mouse secondary antibodies (1:30,000) in TBST containing 5% non-fat milk for 1 
hour at room temperature with agitation followed by TBST washing 4 times at 20 minutes each. 
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Proteins were detected with Proto-Glo ECL (National Diagnostics) and images were taken with a 
Kodak image system. 
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 Results 
 K3L inhibits PKR in a species-specific manner 
To directly assess the inhibitory capability of K3L on PKR from different species, we 
utilized a previously described transfection-based luciferase assay, in which we co-transfected 
plasmids encoding PKR, K3L and firefly luciferase into a line of PKR-deficient HeLa cells 
(described in Chapter 3). We cloned PKR from the following 23 mammalian species: human 
(Homo sapiens), chimpanzee (Pan troglodytes), orangutan (Pongo borneo), gibbon (Hylobates 
leucogenys ), Rhesus macaque (Macaca mulatta), tamarin (Saguinus labiatus), mouse (Mus 
musculus), brown rat (Rattus norvegicus), Guinea pig (Cavia porcellus), Syrian hamster 
(Mesocricetus auratus), Armenian hamster (Cricetulus migratorius), Turkish hamster 
(Mesocricetus brandti), Chinese hamster (Cricetulus griseus), brush rabbit (Sylvilagus 
bachmani), European rabbit (Oryctolagus cuniculus), Eastern cottontails (Sylvilagus floridanus), 
cat (Felis catus), dog (Canis lupus), pig (Sus scrofa), horse (Equus caballus), cow (Bos Taurus), 
camel (Camelus dromedaries) and sheep (Ovis aries). The protein sequences identities between 
these PKRs are shown in Table 2.1. We examined their sensitivities to VACV K3L. First, we 
observed that transfection of PKR alone significantly reduced the expression of luciferase to 
comparable levels among different species, suggesting PKR from different species are expressed 
comparably and are catalytically competent in human HeLa-PKRkd cells (Fig. 2.1). Co-
transfection of K3L with all the PKRs resulted in varied levels of luciferase expression, 
suggesting the inhibition of PKR by K3L is species-specific (Fig. 2.2). Particularly, co-
transfection of K3L resulted in at least a three-fold increase of luciferase activities in cells co-
transfected with PKR from rhesus macaque, tamarin, mouse, Syrian hamster, Turkish hamster, 
Chinese hamster, brush rabbit, European rabbit, Eastern cotton tail, cat, dog, horse, cow and 
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camel, indicating PKR from these species were sensitive to VACV K3L inhibition. In contrast, 
co-transfection of K3L with PKR from human, chimpanzee, rat, Guinea pig, Armenian hamster, 
pig and sheep resulted in none or a slight increase (less than 2 fold) of luciferase activity, 
suggesting PKR from those species are largely resistant, or completely resistant to K3L 
inhibition. PKR from the orangutan or gibbon were only moderately sensitive to K3L inhibition, 
resulting in a 2-3 fold increase of luciferase activity. The results from the transfection assay 
indicate that PKR from different species differ in their sensitivities to inhibition by VACV K3L. 
Interestingly, even some closely related species exhibited very drastic differences in PKR 
sensitivities to K3L inhibition. For instance, whereas mouse PKR was sensitive to K3L, rat PKR 
was completely resistant. A similar phenomenon was also observed between Syrian hamster 
PKR, which was very sensitive to K3L, and Armenian hamster PKR, which was completely 
resistant. In the group of ungulate species tested, PKR from pig and sheep were completely 
resistant to K3L inhibition while PKR from horse, cow and camel species were sensitive. 
In addition to K3L, VACV also contains a second PKR inhibitor, E3L, which is 
composed of a double-stranded RNA binding domain and a Z-DNA binding domain. We 
assessed the inhibitory ability of E3L on PKR from the aforementioned species in the same assay 
and found that E3L was able to increase the reduction of luciferase activity by PKR from most of 
these species with the exceptions of Syrian hamster and Turkish hamster, both of which are 
Mesocricetus hamsters closely related to each other (Fig. 2.3). Interestingly, both Syrian hamster 
and Turkish hamster PKR were very sensitive to K3L inhibition.  
Overall, our data indicate that inhibition of PKR by VACV K3L and E3L is species-
specific. The species-specific inhibition of PKR by VACV K3L follows a random pattern and 
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could not have been predicted with our current knowledge. Meanwhile, VACV E3L displays a 
very low level of species-specificity.  
Variola virus (VARV) is the causative agent of smallpox, which is a deadly infectious 
disease restricted to humans. To examine the inhibitory effect of the VARV K3L ortholog on 
PKR from different species, especially human PKR, we cloned the VARV K3L ortholog, C3L, 
as well as the K3L orthologs from TATP (taterapox virus) and CMLV (camelpox virus), which 
are the closest known relatives of VARV. The TATP and CMLV M96-K3L orthologs display 
93.2% and 92.0% protein sequence identities with VARV C3L, respectively, and 99% identity 
between each other (Fig. 2.4). In the luciferase assay, we found that VARV C3L inhibited PKR 
from gibbon, mouse, brush rabbits, European rabbits, Eastern cottontails, cat, dog, horse, camel 
and sheep with high efficiency (larger than 3-fold increase of luciferase activity) (Fig. 2.5). 
However, in contrast to K3L, VARV C3L failed to inhibit PKR from Syrian, Turkish and 
Chinese hamster species, but instead showed high levels of inhibition of sheep PKR, which was 
resistant to VACV K3L inhibition (Fig. 2.5). Remarkably, human PKR was largely resistant to 
VARV C3L inhibition, showing less than two-fold increase of luciferase activity (Fig. 2.5).  
On the other hand, the TATP K3L ortholog 037 only failed to inhibit PKR from Guinea 
pig and pig, but in contrast to VACV K3L, TATP 037 inhibited PKR from primates, rat, 
Armenian hamster and sheep, which were resistant to VACV K3L (Fig. 2.6). The CMLV K3L 
ortholog V032 from the M96 strain exhibited a very similar pattern of species-specific PKR 
inhibition compared to TATP 037 (Fig. 2.7). The only difference observed between TATP 037 
and CMLV M96-V032 was that Armenian hamster PKR was sensitive to TATP 037, but was 
resistant to CMPV V032 (Fig. 2.6 and 2.7). We also tested the CMLV V032 from the CMS 
strain and found that it was a loss-of-function variant (Fig. 2.8). The PKR sensitivities to 
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poxvirus K3L orthologs from VACV, VARV, TATP and CMLV were summarized in Table 4.2. 
Our results showed that the K3L orthologs from VARV, TATP and CMLV exhibited species-
specific inhibition of PKR. However, the sensitivity of any given PKR to different K3L 
orthologs may vary. For example, human PKR was largely resistant to the inhibitions of VACV 
and VARV K3L orthologs, but was intermediately sensitive to that of the K3L orthologs from 
TATP and CMLV.  
A possible explanation for why human PKR was insensitive to VARV C3L inhibition is 
that human PKR might have evolved to evade inhibition from VARV C3L. This might have 
come with the price that human PKR could have become sensitive to other poxvirus inhibitors by 
chance. To further examine this, we cloned K3L orthologs from 16 poxviruses including VACV, 
VARV, CPXV (cowpox virus), TATP, SPPV (sheeppox virus), DPV (deerpox virus), MYXV 
(myxoma virus), RFV (rabbit fibroma virus), SWPV (swinepox virus), TPV (tanapox virus), 
YMTV (yaba monkey tumor virus), YKV (yoka poxvirus), COTV (cotia virus), RCPV 
(raccoonpox virus), SKPV (skunkpox virus) and VPV (volepox virus). These K3L orthologs are 
highly diverse and can display as low as 22.7% sequence identity with one another (Table 2.3). 
We tested the inhibitory capabilities of these K3L orthologs on human PKR in the luciferase 
assay and found that human PKR exhibited differential sensitivities to different K3L orthologs 
(Fig. 2.9). In consistent with what we observed previously, human PKR was largely resistant to 
VACV K3L and VARV C3L (Fig. 2.9). In addition, we found that human PKR was completely 
resistant to inhibition of MYXV and RFV K3L orthologs, and was largely resistant to the K3L 
orthologs from YKV (Fig. 2.7). Interestingly, the K3L orthologs from SPPV, DPV, TPV, COTV, 
RCPV and SKPV showed strong inhibition on human PKR (Fig. 2.9). As a control, we 
performed the similar test on mouse PKR, which was sensitive to VACV K3L inhibition (Fig. 
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2.9). The results showed that in contrast to human PKR, mouse PKR was resistant to K3L 
orthologs from SPPV, DPV and TPV, which suggest that the reason why human PKR was 
sensitive to these three K3L orthologs was not due to their enhanced expression compared to 
VACV K3L (Fig. 2.10).   
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 Inhibition of PKR is indispensable for VACV replication 
We next determined if the species-specific inhibition of PKR constitutes K3L’s function 
in VACV cell tropism. We infected selected cell lines originated from different species with the 
Copenhagen strain of VACV termed VC-2, or VC-2-derived recombinant viruses including 
vp872 (K3L-knock out), VC-R1 (E3L-knock out), or VC-R2 (E3L, K3L-double knock out) at a 
low MOI (0.01) and monitored replication 48 hours after infection by titering each infection in a 
line of RK13 cells stably expressing K3L and E3L, which is permissive for all viruses (18). In 
addition, we measured phosphorylation of eIF2α six hours after infection with a high MOI 
(MOI=5) as a readout for PKR’s catalytic activity. A previous study from our lab indicated that 
the VC-R2 strain, which lacks both PKR inhibitors K3L and E3L failed to replicate in RK13 
cells, but was able to replicate to slightly lower levels than VC-2, VC-R1 and vp872 in RK13 
cells that stably express PKR inhibitors K3L and E3L, indicating that PKR is the major obstacle 
that VACV has to overcome in order to successfully replicate in these cells (18). Here we show 
that VC-R2, VC-R1 and vp872 were all able to replicate to comparable titers as the wild type 
virus VC-2 in HeLa-PKRkd cells (Fig. 2.11 A). In addition, increased phosphorylation of eIF2α 
was not observed in HeLa-PKRkd cells infected with any strains of VACV (Fig. 2.11 B). These 
results suggest that PKR was the only factor that prevented VACV lacking PKR inhibitors from 
replicating in HeLa cells, and that VACV replication did not lead to the activation of any other 
eIF2α kinases other than PKR.  
Next, we focused on PKR-competent cell lines derived from four different species. We 
first infected Dubca cells and MDCK cells, which were derived from a camel and a dog, 
respectively. The wild type VC-2 strain and the K3L-deficient vp872 strain were able to replicate 
in both Dubca (Fig. 2.12 A) and MDCK (Fig. 2.12 B) cells to comparable titers after 48 hours, 
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suggesting K3L was not required for virus replication in these cell lines. The E3L-deficient VC-
R1 strain was also able to replicate to some extent in both Dubca (Fig. 2.12 A) and MDCK (Fig. 
2.12 B) cells, but not as well as VC-2 and vp872. In addition, the VC-R2 strain failed to replicate 
in either cell line (Fig. 2.12 A, 2.12 B). We also measured eIF2α phosphorylation six hours after 
infection and found that infection with VC-2, vp872 and VC-R1 did not result in increased 
eIF2α phosphorylation compared to mock-infected cells, which correlated with their ability to 
replicate in both cell lines (Fig. 2.13 A, 2.13 B). In contrast, infection with the VC-R2 strain, 
which lacks any PKR inhibitors and was not able to replicate in either cell line, resulted in a 
strong induction of eIF2α phosphorylation in Dubca (Fig. 2.13 A) and MDCK (Fig. 2.13 B) cells. 
All these data suggest that K3L or E3L alone were able to inhibit PKR-induced phosphorylation 
of eIF2α, and to rescue the PKR-mediated suppression of virus replication. These findings 
correlated well with our previous observations that camel and dog PKR were sensitive to both 
K3L and E3L inhibition in the luciferase assay.  
We next infected rat rat-1 cells, derived from a brown rat, and swine PK-15 cells, PKR 
from these corresponding species were sensitive to E3L but completely resistant to K3L 
inhibition. Similar to what we have observed in MDCK and Dubca cells, both VC-2 and vp872 
were able to replicate to comparable levels in rat-1 cells (Fig. 2.14 A) and PK-15 cells (Fig. 2.14 
B). However, we found that VC-R1 and VC-R2, which both lack E3L, failed to replicate in 
either cell line (Fig. 2.14 A, 2.14 B). We also determined eIF2α phosphorylation following virus 
infections and found that infection with VC-2 and vp872 did not induce any eIF2α 
phosphorylation, whereas both VC-R1 and VC-R2 infections led to comparable levels of eIF2α 
phosphorylation in both cell lines (Fig. 2.15 A, 2.15 B). These results suggested that K3L alone 
was not able to inhibit the PKR-mediated phosphorylation of eIF2α and also failed to rescue 
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virus replication, which correlates with our previous observations that rat and swine PKR were 
resistant to K3L inhibition in the luciferase assay. We also tested cat CRFK cells and cow 
MDBK cells, but these cells were non-permissive for VACV and none of the viruses were able 
to replicate in them.  
Overall, our data confirm that successful replication of VACV correlates with effective 
inhibition of PKR during virus infection, and indicates that the species-specific inhibition of 
PKR exhibited by K3L indeed contributes to its host range function for VACV. 
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 Host species-specific inhibition of swine PKR by swinepox virus C8L  
Swinepox virus is a poxvirus that exhibits an extremely narrow host range, infecting only 
pigs. We examined the PKR inhibitory ability of C8L, the K3L ortholog from swinepox virus, 
which displays 44% sequence identity with K3L at the protein level. As shown in Fig. 2.16, co-
transfection of C8L and PKR from mouse, human, Syrian hamster, Armenian hamster, Chinese 
hamster, Guinea pig, rat, European rabbit and chicken resulted in no increase or only small 
increase of luciferase activity, indicating PKR from these species were largely resistant to C8L 
inhibition. In contrast, co-transfection of C8L and swine PKR resulted in a dramatic increase of 
luciferase activity. This observation suggests that swinepox virus C8L may have evolved to 
inhibit swine PKR, but not PKR from other species. This constitutes an example of host species-
specific inhibition of PKR by poxvirus pseudosubstrate inhibitors, and may contribute to the 
mechanism by which swinepox virus infection is restricted in pigs.  
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 Discussion 
K3L was previously shown to be indispensable for VACV replication in Syrian hamster 
BHK21 cells, but not in human HeLa cells, suggesting that K3L is a host range factor (7). 
However, the molecular mechanisms by which K3L exerts its host range function are not fully 
understood. The most commonly used method to study the host range function of a virus gene is 
to examine virus replication in cells derived from various species after deleting or inserting the 
gene in the virus genome. However, this does not yield insights into the interactions between the 
host range proteins and their host interacting/binding partners. We established a cell culture-
based luciferase assay, in which the interaction of PKR and its viral antagonists can be measured 
and represented by relative luciferase activity, allowing us to assess the sensitivity of PKR to 
poxvirus inhibitors (16). Using this assay, we discovered that Syrian hamster PKR is highly 
sensitive to K3L inhibition, while human PKR is largely resistant, which may explains why K3L 
is required for VACV replication only in Syrian hamster BHK21 cells but not in Human HeLa 
cells for VACV replication.  
From the results we obtained from 23 different species, we would have not been able to 
predict PKR’s sensitivity to K3L based on its species origin, such as that all rodent PKR would 
be sensitive. In fact, PKR from even closely related species, e.g. mouse and rat or Syrian hamster 
and Armenian hamster, displayed drastically different sensitivities to K3L inhibition. We 
previously showed that the helix αG region, which contains residues that directly contact eIF2α, 
on the kinase domain of PKR was mainly responsible for its sensitivity to K3L (16). A multiple 
sequence alignment within the helix αG region from 23 PKRs revealed that this region is highly 
diverse with only three residues being conserved across all species compared (Fig. 2.17). This 
finding is striking because eIF2α, the binding substrate of PKR, is highly conserved. How such 
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diverse regions in PKR maintains their interactions with the highly conserved binding partner, 
eIF2α, is still an evolutionary conundrum.  
We divided the 23 PKRs into two groups according to their sensitivities to K3L, being 
either sensitive or resistant using a 3-fold increase of luciferase activity as cut-off between them. 
We then plotted the frequency of amino acids that appearing at each position of the helix αG 
region for each group using WebLogo (22, 23). Unfortunately, we could not immediately 
identify any particular residues or residue combinations that could directly explain the sensitivity 
or resistance of PKR to K3L inhibition. However, we noticed that residues 2, 3, 6, 10, 11, 14 
(indicated by red arrows) were highly diverse across species (Fig. 2.18). We projected these 
residues onto the crystal structure of the kinase domain of human PKR, and found that these 6 
residues are all located at the interacting interface (facing outside) between PKR and eIF2α (Fig. 
2.19, 2.20). This finding suggests that the intermolecular interactions between pseudosubstrate 
inhibitors, such as K3L, and PKR may have driven the divergence of the helix αG region of PKR. 
Interestingly, in the helix αG region, multiple residues (including A488, F489, T491, S492, 
K493, T496 and D500 numbered according to human PKR) were found to be under strong 
positive selection in rodents (personal communication with Sherry Haller), mammals (16) and 
primates (16). This observation further supports the hypothesis that the positive selective 
pressure exerted by virus inhibitors has driven the rapid evolution of the helix αG region on PKR. 
Because we were not able to readily identify signatures between sensitive and resistant PKR, it 
seems that the sensitivity to K3L inhibition is determined by multiple amino acid combinations 
and/or that residues outside of helix αG might contribute to the differences, for example, by the 
spatial orientation of helix αG.  
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Our results showed remarkably that human PKR was largely resistant to the inhibition of 
the VARV K3L ortholog C3L. It is possible that human PKR evolved to evade inhibition from 
C3L as a result of virus-host co-evolution. However, this evasion may come at a price by making 
human PKR more susceptible to K3L orthologs from other poxviruses, such as SPPV, TATP, 
DPV, TPV, COTV, RCPV and SKPV as determined in our luciferase assay. 
The sensitivities of PKR to K3L and E3L inhibition play important roles in determining 
VACV host ranges as determined by our infection analyses. We observed that deletion of E3L 
from VACV did not affect the virus’ ability to suppress eIF2α phosphorylation in cell lines in 
which the PKR was sensitive to K3L inhibition, such as camel Dubca and dog MDCK cells. 
However, in cell lines where the endogenous PKR was resistant to K3L inhibition, such as swine 
PK-15 and brown rat rat-1 cells, the presence of K3L alone failed to prevent PKR-mediated 
eIF2α phosphorylation or rescue virus replication. All these data demonstrate that the host range 
function of K3L is mainly due to its varied ability to inhibit different species’ PKR. 
Swinepox virus is the causative agent of swinepox, a disease strictly restricted to pigs 
(24). Piglets younger than 4-months old are very susceptible to swinepox and can develop an 
acute disease. Adult animals infected with swinepox virus usually develop a mild disease that is 
non-lethal (24). The high host specificity and low virulence of swinepox virus have stimulated 
interest in developing swinepox virus as pig-specific vaccine vector for other infectious diseases 
in pigs (25). However, the molecular mechanism by which swinepox infection is restricted in 
swine is unknown. We showed that the swinepox virus K3L ortholog C8L specifically inhibited 
swine PKR with the highest efficiency. This host species-specific inhibition of PKR may 
contribute to the restriction of swinepox virus to pigs.  
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In conclusion, we studied the inhibitory effect of K3L and its poxvirus ortholog and 
found that inhibition of PKR by K3L orthologs is species-specific, and this finding may 
contribute to the molecular mechanism by which K3L and its poxvirus orthologs exert their host 
range functions.   
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Figure 2.1 Reduction of luciferase translation by PKR 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and empty vector pSG5 (0.4µg). Luciferase 
activity was measured 48 hours after transfection. Experiments were performed in triplicate and 
the results are representative of three independent experiments. Error bars indicate standard 
deviations. Abbreviations used: R=Rhesus; G=Guinea; S=Syrian; A=Armenian; T=Turkish, 
C=Chinese; b=brush; E=European; ct=cottontail.  
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Figure 2.2 Inhibition of PKR by VACV K3L 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and VACV K3L (0.4µg). Luciferase activity 
was measured 48 hours after transfection and the acquired light units were normalized to PKR-
only transfected cells to obtain relative luciferase activities. Experiments were performed in 
triplicate and the results are representative of three independent experiments. Error bars indicate 
standard deviations. Abbreviations used: R=Rhesus; G=Guinea; S=Syrian; A=Armenian; 
T=Turkish, C=Chinese; b=brush; E=European; ct=cottontail.  
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Figure 2.3 Inhibition of PKR by VACV E3L 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and VACV E3L (0.4µg). Luciferase activity 
was measured 48 hours after transfection and the acquired light units were normalized to PKR-
only transfected cells to obtain relative luciferase activities. Experiments were performed in 
triplicate and the results are representative of three independent experiments. Error bars indicate 
standard deviations. Abbreviations used: R=Rhesus; G=Guinea; S=Syrian; A=Armenian; 
T=Turkish, C=Chinese; b=brush; E=European; ct=cottontail. 
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Figure 2.4 Comparison of poxvirus K3L orthologs 
 
Sequences alignment was performed using the program MUSCLE (url: 
http://www.ebi.ac.uk/Tools/msa/muscle). Conserved residues (100% identical) are highlighted in 
yellow.   
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Figure 2.5 Inhibition of PKR by VARV C3L 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and VARV C3L (0.4µg). Luciferase activity 
was measured 48 hours after transfection and the acquired light units were normalized to PKR-
only transfected cells to obtain relative luciferase activities. Experiments were performed in 
triplicate and the results are representative of three independent experiments. Error bars indicate 
standard deviations. Abbreviations used: R=Rhesus; G=Guinea; S=Syrian; A=Armenian; 
T=Turkish, C=Chinese; b=brush; E=European; ct=cottontail. 
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Figure 2.6 Inhibition of PKR by TATP 037 
 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and TATP 037 (0.4µg). Luciferase activity 
was measured 48 hours after transfection and the acquired light units were normalized to PKR-
only transfected cells to obtain relative luciferase activities. Experiments were performed in 
triplicate and the results are representative of three independent experiments. Error bars indicate 
standard deviations. Abbreviations used: R=Rhesus; G=Guinea; S=Syrian; A=Armenian; 
T=Turkish, C=Chinese; b=brush; E=European; ct=cottontail.  
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Figure 2.7 Inhibition of PKR by CMLV M96-V032 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and CMLV V032 (0.4µg). Luciferase activity 
was measured 48 hours after transfection and the acquired light units were normalized to PKR-
only transfected cells to obtain relative luciferase activities. Experiments were performed in 
triplicate and the results are representative of three independent experiments. Error bars indicate 
standard deviations. Abbreviations used: R=Rhesus; G=Guinea; S=Syrian; A=Armenian; 
T=Turkish, C=Chinese; b=brush; E=European; ct=cottontail.  
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Figure 2.8 Inhibition of PKR by CMLV CMS-V032 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and CMLV CMS-V032 (0.4µg). Luciferase 
activity was measured 48 hours after transfection and the acquired light units were normalized to 
PKR-only transfected cells to obtain relative luciferase activities. Experiments were performed in 
triplicate and the results are representative of three independent experiments. Error bars indicate 
standard deviations. Abbreviations used: R=Rhesus; G=Guinea; S=Syrian; A=Armenian; 
T=Turkish, C=Chinese; b=brush; E=European; ct=cottontail. 
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Figure 2.9 Inhibition of human and mouse PKR by poxvirus K3L orthologs 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), human or mouse PKR (0.2µg) K3L orthologs from the indicated poxviruses (0.8µg). 
Luciferase activity was measured 48 hours after transfection and the acquired light units were 
normalized to human PKR-only transfected cells to obtain relative luciferase activities. 
Experiments were performed in triplicate and the results are representative of three independent 
experiments. Error bars indicate standard deviations. Poxvirus species are shown above the lines, 
genera are indicated below the blue lines. Abbreviations: VACV=vaccinia virus; VARV=variola 
virus; CPXV=cowpox virus; TATP=taterapox virus; SPPV=sheeppox virus; DPV=deerpox 
virus; MYXV=myxoma virus; RFV=rabbit fibroma virus; SWPV=swinepox virus; 
TPV=tanapox virus; YMTV=yaba monkey tumor virus; YKV=yoka poxvirus; COTV=cotia 
virus; RCPV=racoonpox virus; SKPV=skunkpox virus; VPV=volepox virus; 
CePV=Cervidpoxvirus; CaPV=Capripoxvirus; SPV=Suipoxvirus.   
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Figure 2.10 Expression of K3L orthologs 
 
Monolayers of HeLa-PKRkd cells in 6-well plates were transfected with FLAG-tagged 
poxvirus K3L orthologs (3µg/well). Protein lysates were collected 48 hours later and were 
subjected to Western blot analyses. PVDF membranes were probed with anti-FLAG antibodies 
followed by anti-β-actin antibodies. Abbreviations: VACV=vaccinia virus; VARV=variola virus; 
CPXV=cowpox virus; TATP=taterapox virus; SPPV=sheeppox virus; DPV=deerpox virus; 
MYXV=myxoma virus; RFV=rabbit fibroma virus; SWPV=swinepox virus; TPV=tanapox 
virus; YMTV=yaba monkey tumor virus; YKV=yoka poxvirus; COTV=cotia virus; 
RCPV=racoonpox virus; SKPV=skunkpox virus; VPV=volepox virus;  
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Figure 2.11 VACV infection in HeLa cells 
 
(A) Confluent monolayers of HeLa-PKRkd cells in 6-well plates were infected with VC-2 
(Copenhagen wild type), VC-R1 (E3L-deficient), vp872 (K3L-deficient) and VC-R2 (K3L-
deficient/E3L-deficient) at an MOI of 0.01. Viruses were collected 0 and 48 hours post infections 
and titered on RK13 cells that stably express VACV E3L and K3L. (B) Confluent monolayers of 
HeLa-PKRkd cells in 6-well plates were infected with the indicated virus strains at an MOI of 5. 
Total protein lysates were collected 6 hours post infection and separated on SDS-PAGE gels 
followed by Western blot analyses. The blocked membranes were first incubated with anti-
phospho-51 eIF2α antibody, then stripped and reprobed with antibody against total eIF2α.   
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Figure 2.12 Replication of VACV in Dubca and MDCK cells 
 
Confluent monolayers of camel Dubca cells (A) or canine MDCK cells (B) in 6-well 
plates were infected with VC-2 (Copenhagen wild type), VC-R1 (E3L-deficient), vp872 (K3L-
deficient) and VC-R2 (K3L-deficient/E3L-deficient) at an MOI of 0.01. Viruses were collected 0 
and 48 hours post infections and tittered on RK13 cells that stably express VACV E3L and K3L. 
Infections were performed in duplicate and error bars indicate standard deviation.  
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Figure 2.13 Phosphorylation of eIF2α in VACV-infected Dubca and MDCK cells 
 
Confluent monolayers of camel Dubca cells (A) or canine MDCK cells (B) in 6-well 
plates were infected with VC-2 (Copenhagen wild type), VC-R1 (E3L-deficient), vp872 (K3L-
deficient) and VC-R2 (K3L-deficient/E3L-deficient) at an MOI of 5. Total protein lysates were 
collected 6 hours post infection and separated on SDS-PAGE gels followed by Western blot 
analyses. The blocked membranes were first incubated with anti-phospho-51 eIF2α antibody, 
then stripped and re-probed with antibody against total eIF2α. 
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Figure 2.14 Replication of VACV in rat-1 and PK-15 cells 
 
Confluent monolayers of brown rat rat-1 cells (A) and swine PK-15 cells (B) in 6-well 
plates were infected with VC-2 (Copenhagen wild type), VC-R1 (E3L-deficient), vp872 (K3L-
deficient) and VC-R2 (K3L-deficient/E3L-deficient) at an MOI of 0.01. Viruses were collected 0 
and 48 hours post infection and tittered on RK13 cells that stably express VACV E3L and K3L. 
Infections were performed in duplicate and error bars indicate standard deviation.  
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Figure 2.15 Phosphorylation of eIF2α in VACV-infected rat-1 and PK-15 cells 
 
Confluent monolayers of brown rat rat-1 cells (A) and swine PK-15 cells (B) in 6-well 
plates were infected with VC-2 (Copenhagen wild type), VC-R1 (E3L-deficient), vp872 (K3L-
deficient) and VC-R2 (K3L-deficient/E3L-deficient) at an MOI of 5. Total protein lysates were 
collected 6 hours post infection and separated on SDS-PAGE gels followed by Western blot 
analyses. The blocked membranes were first incubated with anti-phospho-51 eIF2α antibody, 
then stripped and re-probed with antibody against total eIF2α. 
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Figure 2.16 Host species-specific inhibition of swine PKR by swinepox virus C8L 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), PKR from the indicated species (0.2µg) and the swinepox virus C8L (0.4µg). 
Luciferase activity was measured 48 hours after transfection and the acquired light units were 
normalized to PKR-only transfected cells to obtain relative luciferase activities. Experiments 
were performed in triplicate and the results are representative of three independent experiments. 
Error bars indicate standard deviations.  
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Figure 2.17 Sequences alignment of the helix αG region on PKR 
 
PKR from the indicated species were classified into three groups: Sensitive, largely 
resistant and resistant according to their sensitivities to VACV K3L as determined in the 
luciferase assay. The protein sequences of the helix αG regions from each PKR were aligned and 
conserved amino acids (100% conservation) are highlighted in blue.  
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Figure 2.18 The helix αG region of PKR is highly divergent 
 
Sequences were generated using the tool WebLogo (Version 2.8.2 2005-09-08, url: 
http://weblogo.berkeley.edu) (22-23) based on the multiple sequence alignment shown in Fig 
4.10. Red arrows indicate highly divergent residues.  
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Figure 2.19 Structure of the PKR-eIF2α complex 
 
Structure of the PKR-eIF2α complex was adapted from RCSB PDB 2A1A (17). The 
residues comprising the helix αG were colored in yellow on the PKR structure. Residues that are 
highly divergent are colored in red. Arrows indicate residues under positive selection. Color-
coded arrows indicate residues identified as being under positive selection. Different colors of 
arrows indicate different sources of positive selection analyses: blue: personal communication 
with Sherry Haller; red: Rothenburg et al (16); Orange: Elde et al. (17). 
  
70 
 
 
 
Figure 2.20 Structure of the kinase domain of PKR 
 
The structure of the kinase domain of PKR was adapted from PDB 2A1A (17). The 
residues directly interacting with eIF2α are colored in yellow and residues that are highly 
divergent are indicated by red circles. Residues in boxes are those being under positive selective 
pressure. Boxes are color coded based on the source of the positive selection analyses: Blue: 
personal communication with Sherry Haller. Red: Rothenburg et al. (16). Orange: Elde et al. 
(17). 
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Table 2.1 PKR sequence identity 
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Table 2.2 Inhibition of PKR by K3L orthologs represented by fold increases of luciferase 
activities 
 
Fold increases caused by co-transfection of VACV K3L, VARV C3L, TATP037, CMLV 
M96-V032 or CMLV CMS-V032 and PKR from the indicated species were summarized in the 
table. Red asterisk indicate complete inhibition.   
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Table 2.3 Sequence identities between K3L orthologs 
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 Abstract 
Myxoma virus (MYXV) is a rabbit-specific poxvirus, which is highly virulent in 
European rabbits. The attenuation of MYXV and the increased resistance of rabbits following the 
release of MYXV in Australia is one of the best-documented examples of host-pathogen co-
evolution. To elucidate the molecular mechanisms that contribute to the restriction of MYXV 
infection to rabbits and MYXV attenuation in the field, we have studied the interaction of the 
MYXV protein M156 with the host antiviral protein kinase R (PKR). In yeast and cell-culture 
transfection assays M156 only inhibited rabbit PKR but not PKR from other tested mammalian 
species. Infection assays with human HeLa PKR knock-down cells, which were stably 
transfected with human or rabbit PKR, revealed that only human but not rabbit PKR was able to 
restrict MYXV infection, whereas both PKRs were able to restrict replication of a vaccinia virus 
(VACV) strain that lacks the PKR inhibitors E3L and K3L. Inactivation of M156R led to MYXV 
virus attenuation in rabbit cells, which was rescued by the ectopic expression of VACV E3 and 
K3. We further show that a mutation in the M156 encoding gene that was identified in more than 
50% of MYXV field isolates from Australia resulted in an M156 variant that lost its ability to 
inhibit rabbit PKR and led to virus attenuation. The species-specific inhibition of rabbit PKR by 
M156 and the M156 loss-of-function in Australian MYXV field isolates might thus contribute to 
the species-specificity of MYXV and to the attenuation in the field, respectively. 
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 Significance 
The virulence and host range of viruses is controlled by the interaction of the host innate 
immune system with viral molecules. This interaction is an important driver for the evolution of 
both the host and the virus. The attenuation of myxoma virus, a rabbit specific poxvirus, after its 
deliberate release to control European rabbit populations, and the increased resistance of the 
rabbits, is one of the best-known examples for host-virus co-evolution on the population level. 
We show that the myxoma virus protein M156 specifically inhibited the antiviral protein kinase 
R (PKR) from rabbits but not PKR from other mammals, that PKR inhibition correlated with 
virus replication during infection and that M156 contains a loss-of-function mutation in 
Australian field isolates. 
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 Introduction 
Poxviruses are large double-stranded DNA viruses that exclusively replicate in the 
cytoplasm of infected cells. Members of the Poxviridae family can productively infect a wide 
variety of animal hosts. Interestingly, the binding and entry of poxviruses into cells is largely 
independent of host species after which virus replication is initiated. The successful completion 
of virus replication, however, depends on the effective subversion of the host cell’s innate 
immune responses (1). Even closely related poxviruses can exhibit drastic differences in their 
host ranges. Whereas some poxviruses have only one host-species, such as variola virus, the 
causative agent of smallpox, which is restricted to humans, others, such as cowpox and 
monkeypox viruses, can infect many different species and thus display very broad host ranges 
(2). A number of poxvirus genes have been discovered that influence the host range and cell 
tropism of poxviruses and have therefore been termed “host range genes” (3, 4). Although the 
molecular mechanisms responsible for their host range functions have not been elucidated in 
detail, it is clear that most poxviral host range proteins interact with components of the host 
immune system and that host species-specific interactions likely play a major role. 
Myxoma virus (MYXV) is a poxvirus that belongs to the genus leporipoxvirus and shows 
a restricted host range infecting only leporids (rabbits and hares). MYXV is highly lethal to 
European (E.) rabbits causing case fatality rates (CFRs) of close to 100%. Since 1950, MYXV 
was repeatedly introduced into Australia to combat the invasive feral E. rabbit population, which 
has caused ecological and economical havoc. Shortly after the release of the MYXV standard 
laboratory strain (SLS), which caused a CFR of 99.8% in laboratory rabbits (grade 1 virulence), 
attenuated virus strains began to appear in the wild and started to outcompete the more virulent 
parental strain. The predominant strains found in the field are of grade 3 and grade 4 virulence 
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and exhibit a CFR in laboratory rabbits between 70-95% and 50-70%, respectively. 
Concomitantly, rabbits evolved increased resistance to MYXV infection. Evolution of attenuated 
MYXV and increased resistance of rabbits to infection were also observed after the illegal 
release of MYXV in Europe (reviewed in (5)). The molecular mechanisms of the attenuation of 
MYXV and the increased resistance of rabbits to infection are unknown. Recently, the complete 
genomes of 24 MYXV strains that were collected in the field in Australia were reported. 
Although a number of mutations were discovered, it was not immediately clear which mutations 
led to changes in MYXV virulence (6, 7). Two candidate genes that might contribute to changes 
in virulence are M029L and M156R, the MYXV orthologs of vaccinia virus (VACV) E3L and 
K3L, respectively. VACV E3L and K3L are virulence and host range genes, and their protein 
products E3 and K3 inhibit the activation and activity of PKR (8, 9). PKR is an antiviral protein 
that is found in most vertebrates. It is constitutively expressed at moderate levels and can be 
induced by type I interferons. PKR is composed of two N-terminal double-stranded RNA 
(dsRNA) binding domains that sense viral dsRNA, and a C-terminal kinase domain. Upon 
binding to dsRNA, two inactive PKR monomers dimerize and undergo autophosphorylation. 
Activated PKR subsequently phosphorylates the alpha subunit of eukaryotic translation initiation 
factor 2 (eIF2), which leads to the general suppression of protein translation and inhibition of 
virus replication. During vertebrate evolution PKR has evolved rapidly, likely as a consequence 
of positive selective pressure exerted by viral PKR antagonists. We and others previously 
showed that VACV K3 inhibits PKR in a species-specific manner, e.g. whereas mouse PKR was 
sensitive to K3 inhibition, human PKR was largely resistant (10, 11). MYXV 156 is a homolog 
of eIF2α and was previously tested for its ability to inhibit human PKR in a heterologous yeast 
assay in which it showed no inhibition of human PKR activity (12)
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hypothesis that M156R evolved to inhibit rabbit PKR and that species-specific inhibition of PKR 
contributes to the restricted host range of MYXV to rabbits. We further tested whether variations 
found in MYXV field isolates affected the inhibitory potential of M156 and M029 against rabbit 
PKR. 
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 Results 
 Predominant Expression of a Short M156 Form 
M156R is located at the 3’ end of the genome and partly overlaps with the inverted 
terminal repeat (ITR) region in the reference Lausanne (Lu) strain (13). Among all known 
poxvirus K3 orthologs, M156 is unique, because it contains a predicted N-terminal extension, 
based on an elongated ORF (open reading frame) (Fig. 3.1A, 3.6A). In MYXV strains that 
descended from South America, M156R is annotated to encode a 102-amino acid protein with a 
predicted molecular mass of 12 kDa (13). The M156 orthologs of the closest relatives, rabbit 
fibroma virus and the Californian MYXV MSW strain, lack this putative extension, but contain a 
putative start codon that encodes for 78- and 77-aa-long ORFs, respectively, with predicted 
molecular masses of 9 kDa (Fig. 3.6A) (14, 15). A putative start codon at the corresponding 
position is also found in the South American-derived MYXV strains. In the solution structure of 
M156, for which the long M156R ORF was used, the first 32 amino acids were unstructured 
(12). A predicted poxvirus early promoter motif is absent in the 500 bp 5’ to the first start codon, 
but is present at nucleotide position -42 relative to the second predicted start codon (Fig. 3.6B). 
To determine the authentic ORF of M156R, we performed rapid amplification of cDNA ends 
(RACE) PCR to determine the transcriptional start sites (TSSs) using total RNA from MYXV-
Lu-infected RK13 cells 4, 12 or 24 h post infection (hpi). Prominent bands were observed at 
about 120 bp at all time points but not in the uninfected control (Fig. 3.6C). PCR products were 
randomly cloned and sequenced. TSSs of 17 out of 18 clones started within the extended ORF, 
with the majority (82%) of sequences starting at positions -15 to -7 relative to the second start 
codon (Fig. 3.6B and Fig. 3.7). None of the discovered TSSs are predicted to lead to the 
translation of the long M156 isoform. To analyze the expression pattern of M156 and compare 
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its molecular mass to that of transfected M156, we performed Western blot analyses of RK13 
cells infected with Lu MYXV at various time points (Fig. 3.6D). M156 expression was detected 
as early as 1 hpi and was most strongly expressed after 4-24 hpi and thus showed comparable 
expression to M-T7, an early expressed MYXV protein. In contrast, expression of the late 
protein M130 was not observed until 8 hpi. We also transfected RK13 cells with plasmids 
encoding the short or long M156 isoforms and analyzed their expression using anti-M156 serum. 
The short M156 isoform (Fig. 3.6D, lane 7) was detected at a comparable size as M156 in 
MYXV-infected cells. We were unable to detect the expression of the long M156 isoform under 
any conditions using our M156 antiserum. In conclusion, our data indicate that the short form of 
M156 is the predominant isoform in the tested cells, and we therefore used this version in 
subsequent experiments. To avoid confusion with M156R annotations of MYXV genomes, we 
kept the numbering of the long isoform when referring to specific amino acids. 
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 Host-Specific PKR Inhibition by M156 
Yeast-based assays have been previously used to analyze interactions of PKR and viral 
inhibitors (10, 11, 16-18). In one of these assays, M156 failed to inhibit human PKR, whereas its 
VACV ortholog K3 showed PKR inhibition (12). We hypothesized that M156R evolved to 
inhibit rabbit PKR. To test this hypothesis, we generated isogenic yeast strains that were stably 
transformed with empty vector (control), human PKR, or E. rabbit PKR under the control of a 
galactose-inducible promoter (18). These strains were subsequently transformed with plasmids 
encoding VACV K3, MYXV M156, or empty vector (control), which are also under the control 
of the galactose-inducible promoter. Under inducing conditions (galactose-containing agar 
plates), all transformants of the control strain expressing no PKR showed comparable growth, 
indicating that K3 or M156 alone had no effect on yeast growth (Fig. 3.1B). Induction of both 
human and E. rabbit PKR expression was toxic in the vector-transformed strains, whereas this 
toxicity was suppressed by K3 (Fig. 3.1C, 3.1D). Expression of M156 had no effect on human 
PKR toxicity, whereas it reduced toxicity of E. rabbit PKR, as indicated by no growth and 
growth, respectively (Fig. 3.1C, 3.1D). The transformants were also grown in liquid media to 
measure eIF2α phosphorylation levels 4 h after galactose induction by Western blot analysis. No 
eIF2α phosphorylation was observed in the absence of PKR (Fig. 3.1E). Both human and E. 
rabbit PKR induced eIF2α phosphorylation, which was reduced by the expression of K3 for both 
PKR. Expression of M156 only inhibited eIF2α phosphorylation induced by E. rabbit PKR, but 
not that mediated by human PKR. These results demonstrate that M156 is an inhibitor of E. 
rabbit PKR but not of human PKR in this yeast assay and also explain why no inhibition of 
human PKR was observed previously (12). 
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To extend the analysis of host-specific PKR inhibition by M156, we used a previously 
described assay in HeLa cells, in which the endogenous PKR was stably knocked down by 
shRNA, designated as HeLa-PKRkd cells (10). To avoid the effect of RNA interference on 
transfected human PKR, we used knock-down resistant human PKR (PKRkd-res) for subsequent 
experiments. HeLa-PKRkd cells were cotransfected with E. rabbit, human, sheep, mouse, rat, 
Guinea pig, Syrian hamster or Chinese hamster PKR, M156R or a control plasmid (empty 
vector), and firefly luciferase. Our previous studies showed that the reduction of luciferase 
activity is a more sensitive indicator of PKR activity than phosphorylation of eIF2α in transient 
transfection assays (10). Luciferase activities were normalized to PKR-only transfected cells. 
Increases in luciferase activity indicate inhibition of PKR activity. Transfection of M156R 
resulted in strongly increased luciferase expression only in cells cotransfected with E. rabbit but 
not in cells co-transfected with the other species’ PKRs, which indicates that M156 inhibited 
only E. rabbit PKR, whereas the other species’ PKRs were resistant (Fig. 3.2A). This result 
therefore confirms and extends the results of species-specific M156 activity obtained in the yeast 
assays. Because MYXV contains a second PKR inhibitor encoded by M029L, which belongs to 
the poxvirus E3L family of dsRNA-binding proteins, we analyzed whether M029 also exhibits 
species-specific PKR inhibitory activity. HeLa-PKRkd cells were cotransfected with human or E. 
rabbit PKR and increasing amounts of M029L or M156R. Whereas E. rabbit PKR but not human 
PKR was inhibited in a dose-dependent manner by M156, both PKRs showed comparable 
sensitivity to M029, indicating that only M156 exhibits pronounced species specificity (Fig. 3.2B 
and 3.2C). Myxoma virus proteins M-T5, M011, M013 and M130, used as controls, had no 
effect on PKR activity (Fig. 3.8). 
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 Myxoma Virus Can Overcome the Antiviral Effects of Rabbit PKR 
To characterize the antiviral effects of E. rabbit and human PKR during poxvirus 
infection, we established an infection assay using HeLa-PKRkd cells in which we stably 
expressed PKR. To mimic natural PKR expression, we constructed a plasmid that contains the 
human PKR promoter as characterized (19), followed by the rabbit β-globin intron and a 
multiple cloning site, into which we cloned human PKRkd-res or E. rabbit PKR, followed by two 
FLAG tags. HeLa-PKRkd cells were stably transfected with the PKR-expressing plasmids or 
empty vector and clones derived from single colonies were analyzed for PKR expression. For 
subsequent experiments, a clone (h14) that expressed transgenic human PKR (HeLa-
PKRkd+humanPKR) at levels comparable to that of control HeLa cells was chosen, as determined by 
Western blot using an anti-human PKR antibody (Fig. 3.9). An E. rabbit PKR-expressing clone 
(r15, HeLa-PKRkd+E. rabbit PKR) was chosen that showed comparable PKR expression to that of 
HeLa-PKRkd+humanPKR, using an anti-FLAG tag antibody (Fig. 3.9). HeLa control cells, as well as 
HeLa-PKRkd and its derivatives stably transfected with vector, human, or rabbit PKR were 
infected with VC-R2, a VACV strain that lacks both PKR inhibitors K3 and E3, to analyze if 
VACV replication is suppressed when PKR is expressed. In VC-R2, the E3L gene is replaced 
with a destabilized EGFP driven by the native E3L promoter and its expression can be used as 
readout for VACV protein expression. EGFP was expressed in HeLa-PKRkd and HeLa-
PKRkd+vector cells, whereas it was strongly suppressed in HeLa control cells and HeLa-PKRkd 
cells expressing human and E. rabbit PKR (Fig. 3.3A). We also determined VC-R2 replication in 
the infected cells by performing plaque assays on rabbit RK13 cells expressing E3 and K3, 
which are permissive for VC-R2. VC-R2 could only replicate in HeLa-PKRkd and HeLa-
PKRkd+vector, whereas endogenous levels of PKR expression completely suppressed VC-R2 
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replication (Fig. 3.3B). These results demonstrate that transgenic expression of either human or 
E. rabbit PKR can compensate for the loss of PKR in HeLa cells with respect to the suppression 
of VACV replication. We next infected the same cell lines with MYXV that expresses EGFP 
under the control of a synthetic early/late poxvirus promoter (20). In HeLa control and HeLa-
PKRkd+humanPKR cells, relatively weak EGFP expression was observed, whereas strong EGFP was 
observed in PKR-deficient and E. rabbit PKR-expressing cells (Fig. 3.3A). This observation 
correlated with MYXV replication in these cells, which was only suppressed in cells expressing 
human PKR but not E. rabbit PKR (Fig. 3.3B). We also monitored eIF2α phosphorylation levels 
in mock- and virus-infected congenic HeLa cells by Western blot analyses to assess whether the 
effects of transgene expression on virus replication correlated with eIF2α phosphorylation. In 
HeLa-PKRkd and HeLa-PKRkd+vector cells, basal eIF2α phosphorylation levels were not increased 
by VC-R2 or MYXV infection (Fig. 3.3C). In HeLa-PKRkd+humanPKR and HeLa-PKRkd+E. rabbit PKR 
cells, VC-R2 infection induced strong eIF2α phosphorylation to levels comparable to that in the 
HeLa control cells. MYXV infection only led to increased eIF2α phosphorylation in HeLa 
control and HeLa-PKRkd+humanPKR cells, which express human PKR, but not in HeLa-PKRkd, 
HeLa-PKRkd+vector, and cells expressing E. rabbit PKR (Fig. 3.3C). Thus, the effects of PKR on 
virus replication correlated well with eIF2α phosphorylation levels. The combined results show 
that MYXV was resistant to the antiviral effects of E. rabbit PKR but sensitive to those of human 
PKR. 
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 M156 Deficiency Leads to MYXV Attenuation in Rabbit Cells  
We inactivated M156R in MYXV-M029LKO, which lacks the other PKR inhibitor M029 
(21), to generate MYXV-M029LKOM156RKO, which is devoid of both PKR inhibitors (Fig. 
3.10). Deletion of M029L alone resulted in smaller plaque sizes and approximately 10- to 50-fold 
titer reduction in infected RK13 cells (21) (Fig 3.4A and 3.4B). Inactivation of M156R in this 
strain resulted in further attenuation as indicated by the reduced EGFP expression and an 
additional 10- to 17-fold titer reduction (Fig 3.4A and 3.4B). Viral protein synthesis was 
abolished in MYXV-M029LKOM156RKO as indicated by the absence of M-T7 and M130 
expression (Fig 3.4C). In RK13+E3L+K3L, replication and protein synthesis of MYXV-
M029LKOM156RKO were not impaired, indicating that the attenuation of this strain is caused by 
its inability to inhibit PKR. Interestingly, we consistently observed higher expression of the early 
proteins M156 and M-T7 in both RK13 and RK13+E3L+K3L cells infected with MYXV-
M029LKO, which indicates that M029 might be a negative regulator of some MYXV proteins’ 
expression. 
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 Loss-of-Function Mutation in M156R of Australian MYXV Isolates 
Despite the availability of the full genome sequences of 24 MYXV isolates from 
Australia, the molecular mechanisms that underlie the attenuation of MYXV strains in the field 
are currently unclear. One of the identified mutations leads to a predicted leucine-to-proline 
amino acid substitution at position 98 (L98P) in M156R in 13 out of 24 isolates (7). The 
corresponding leucine residue in the costructure of eIF2α with human PKR (22) is shown in Fig. 
3.5A. We introduced this mutation into M156-encoding plasmids using site-directed mutagenesis 
and tested its effect on E. rabbit PKR in yeast and cell culture assays. The mutation had no effect 
on yeast growth in a control strain, but abolished the M156-mediated rescue of yeast growth in a 
strain expressing rabbit PKR (Fig. 3.5B and 3.5C). In correlation with this result, M156-L98P 
was unable to inhibit M156-mediated inhibition of eIF2α phosphorylation in yeast grown in 
liquid medium (Fig. 3.5D). The inability of M156-L98P to inhibit PKR was also confirmed in 
the cell-culture-based transfection assays, in which even the highest amounts of M156-L98P had 
no effect on PKR activity (Fig. 3.5E). In transfected cells, both M156 and M156-L98P were 
expressed at comparable levels as determined by Western blot analysis and the loss of PKR 
inhibition was therefore not due to altered M156 expression (Fig. 3.5E). A predicted alanine-to-
valine substitution at position 17 in M029, which was present in 11 out of 24 isolates (7), did not 
result in altered PKR inhibition (Fig. 3.11). To test the effect of M156-L98P in MYXV infection, 
we inserted it or wild type M156R (revertant) into MYXV-M029LKOM156RKO and infected 
RK13 cells with the viruses. M156 was able to restore EGFP expression, whereas M156-L98P 
could not (Fig 3.5F). EGFP expression correlated well with virus replication, which was restored 
by M156 but not by M156-L98P (Fig 3.5G), confirming that the latter is also a loss-of-function 
mutation in the context of MYXV infection. The loss of M156 function in some MYXV isolates 
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is thus a good candidate for a contributing factor to the virulence attenuation of MYXV in 
Australia. 
  
92 
 Discussion 
We have shown here that M156 of MYXV is a species-specific inhibitor of rabbit PKR, 
that human PKR but not rabbit PKR can restrict MYXV replication in congenic HeLa cells, and 
that M156 deficiency leads to virus attenuation in RK13 cells. The extent of species-specific 
PKR inhibition by M156 is remarkable, considering its likely mode of action as a 
pseudosubstrate inhibitor (23). Poxvirus K3 homologs share the common S1 fold with eIF2α, the 
substrate of PKR and they all likely bind to the same region of PKR. In contrast to the poxvirus 
K3 members, which can share as little as 20% sequence identity with each other (10), eIF2α is 
highly conserved, e.g., 100% sequence identity between human and rabbits in the S1 domain. 
The finding that PKR has been evolving rapidly can be explained by the high selective pressure 
exerted by pathogen-derived antagonists, such as poxviral K3 orthologs, which has caused PKR 
to diversify. Still, PKR faces the challenge to maintain its interaction with eIF2α, while evading 
inhibition by K3-family pseudosubstrate inhibitors. The best-studied PKR pseudosubstrate 
inhibitor is VACV K3. It was previously shown that K3 inhibited mouse PKR much better than 
human PKR in cell transfection assays and that hominoid PKR were more resistant to K3 
inhibition than PKR from Old World and New World monkeys in yeast assays, indicating the 
potential for species-specific inhibition (10, 11). A limitation of studying the interaction of 
VACV with host proteins is that its “natural” host is unknown. Studying the interaction of 
MYXV proteins with innate immune proteins of a naturally infected rabbit host can therefore 
provide unique insights into this host-pathogen relationship. Potential species-specificity of 
M156 was not previously considered as an explanation for its inability to inhibit human PKR in a 
yeast assay (12). Our results that only rabbit PKR but not human PKR was inhibited by M156 in 
yeast demonstrate that this assay system is informative and that species-specific activity can 
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explain the earlier negative results obtained in yeast. This finding was confirmed and extended 
by the transfection assays, which showed that of the eight tested mammalian PKRs, only rabbit 
PKR was strongly inhibited by M156. Because MYXV has evolved in rabbits, it can be assumed 
that its gene products adapted to inhibit the immune response of its hosts. However, it is 
remarkable that PKR from other mammals were not considerably affected as “off-species 
targets” because M156 is predicted to bind to the PKR kinase domain at the same interaction 
surface as the PKR target eIF2α. The species-specific PKR inhibition by M156 is the first 
example where a species-specific interaction correlates with the host species restriction of 
MYXV virus. 
The host range function of many poxvirus genes was described in cultured cells that 
originated from different species. Because it cannot be ruled out that cell-specific characteristics 
that are species independent contribute to the observed differences, we established a system that 
allows the comparison of PKR from different species in congenic HeLa cells. Infection of these 
cells showed that human PKR restricted MYXV infection, but that MYXV replicated as well in 
cells expressing rabbit PKR as in cells in which endogenous PKR expression was knocked down. 
Importantly, rabbit PKR was as efficient as human PKR in inhibiting the replication of a VACV 
strain that lacks the PKR inhibitors E3 and K3. These results demonstrate that MYXV can 
overcome the antiviral activities of only rabbit PKR and this correlates with the ability of M156 
to inhibit rabbit PKR but not human PKR. Congenic cells expressing PKR from different species 
might also prove useful for studying species-specific effects of other viral inhibitors. 
The coevolution of both MYXV and the feral European rabbit host after the deliberate 
release of MYXV into Australia and Europe constitutes one of the best-studied examples of host-
virus evolution on the population level. The introduction of MYXV into Australia initially led to 
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a dramatic reduction of the rabbit population; however, within a few years, rabbit numbers 
rebounded. This could be attributed to the increased resistance of rabbits against MYXV and to 
the attenuation of MYXV in the field, the latter of which allowed for more efficient virus 
transmission (5). The molecular mechanisms behind these two phenomena are, however, poorly 
understood. The full genome sequencing of 24 MYXV that were isolated between 1951 and 
1999 constituted an important step in understanding the molecular basis for MYXV evolution in 
Australia. While many mutations were present in the isolates, no common mutations were 
identified that could explain differences in virulence (6, 7). The L98P mutation in M156R was 
identified in 13 of these isolates. Because M156R-L98P was unable to inhibit rabbit PKR and led 
to MYXV attenuation in our assays (Fig. 3.5), this mutation can help explain and likely 
contributes to the attenuation of MYXV in Australia. The corresponding residue in eIF2α and 
viral homologs is highly conserved, being either a leucine in eIF2α and vIF2α, a PKR inhibitor 
from ranaviruses and leporipoxvirus 156R, or a valine in K3/M156 orthologs from other 
poxviruses (18). This residue is part of a β-sheet (β5), which also comprises residues 
corresponding to M156 Y95 and D97, which are 100% conserved in all eIF2α homologs and are 
involved in the binding of eIF2α to PKR (12, 18, 22). A proline in this β-sheet would likely 
disrupt the β-sheet and abolish binding to PKR. Indeed, it would be instructive to know if the 
rabbit PKR locus has also undergone any virus-induced selection pressures over the half century 
since the first field releases of MYXV. 
In conclusion, the results presented here show that rabbit PKR was specifically inhibited 
by M156, that human PKR plays an essential role in suppressing MYXV replication in HeLa 
cells, and that a naturally occurring mutation in M156 abolished rabbit PKR inhibition. These 
phenomena might contribute to the strict host restriction of MYXV infection to only rabbits, the 
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prevention of productive infection in nonrabbit species (particularly humans), and the attenuation 
of MYXV strains currently extant in Australia. Moreover, this study shows that the choice of 
biologically meaningful host-virus systems is important for studying host-virus interactions. 
Often, studies of viral molecules or viruses are performed with molecules, cell lines or animals 
of nonhost species. The results of such experiments could be misleading, if the virus molecules 
act in a species-specific manner as shown here for M156 and rabbit PKR. 
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 Materials and Methods 
Plasmids, Yeast Strains and Cell Lines 
 PKR and viral genes were cloned into pSG5 for expression in mammalian cells. 
Generation of yeast strains, stably transformed with empty vector (J673) or human PKR (J983) 
under the control of a yeast GAL-CYC1 hybrid promoter, was described (18). A yeast strain 
stably transformed with E. rabbit PKR (O8) was generated using the same methods. VACV K3L 
and M156R were cloned into the vector pYX113, which contains the GAL-CYC1 hybrid 
promoter. HeLa-PKRkd cells (24), kindly provided by Charles Samuel, were stably transfected 
with knock-down resistant human PKR and E. rabbit PKR under the control of the human PKR 
promoter (19). The generation of RK13+E3L+K3L cells was described (21). See SI Materials 
and Methods for details. 
 
 RACE PCR 
E. rabbit RK13 cells were infected with MYXV-EGFP at an multiplicity of infection 
(MOI) of 1. Total RNA was collected with TRIzol reagent at 4, 12 and 24 h postinfection. RACE 
PCR was performed with the GeneRacer Core Kit (Invitrogen) according to the manufacturer’s 
instruction. See SI Materials and Methods for details. 
 
 Yeast Growth and eIF2α Phosphorylation Assays  
Experiments were performed as previously described (18, 25). See SI Materials and 
Methods for details. 
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 Luciferase Assay  
5 x 104 HeLa-PKRkd cells were seeded in 24-well plates 1 day before transfection. For 
each transfection, firefly luciferase (pGL3promoter, 0.05µg, Promega), and pSG5 plasmids 
encoding PKR (0.2 µg), M156 or M029 (0.4 µg) were transfected using GenJet-HeLa 
(Signagen). For titration experiments, amounts of transfected plasmids are indicated in the 
figures. For controls, empty pSG5 vector was transfected using the same amount. Each 
transfection was conducted in triplicate. After 48 hours, cell lysates were harvested using 
mammalian lysis buffer (Goldbio) and luciferase activity was determined using luciferase 
detection reagents (Promega) in a luminometer (Berthold). 
 
 Construction of Recombinant Viruses 
The construction of VC-R2 and MYXV-EGFP were described previously (20, 26) and 
the construction of M156R mutant viruses is illustrated in Fig. S5 and described in SI materials 
and methods.  
 
 Infection Assays 
HeLa-control, HeLa-PKRkd, HeLa-PKRkd+vector, HeLa-PKRkd+hPKR and HeLa-
PKRkd+E.rabbit PKR cells were seeded into six-well plates and confluent monolayers (1x106 cells) 
were mock infected with PBS or infected with VC-R2 and MYXV-EGFP at an MOI of 0.1 and 
1, respectively. RK13 cells were infected with MYXV-EGFP or MYXV-EGFP-derived 
recombinant viruses at an MOI of 5. Fluorescent pictures were taken with an inverted fluorescent 
microscope (Leica) and viruses were collected at 0, 24, 48 and 72 hpi for titration in RK13 cells 
that stably express E3 and K3. See SI Materials and Methods for details. 
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 Western blot analyses 
Protein lysates from RK13 cells that were infected with MYXV-EGFP (MOI = 10) were 
blotted on PVDF membranes and incubated with anti-M156 (27), and after stripping, re-probed 
with anti-serum against M-T7 (28), M130 (29) and anti-β-actin. For eIF2α phosphorylation 
assays, PKR-expressing cells were infected with VC-R2 or MYXV-EGFP at an MOI of 5. Total 
protein lysates were collected 8 hpi and eIF2α was detected with phospho-specific eIF2α and 
total eIF2α. See SI Materials and Methods for details. 
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Figure 3.1 M156 inhibits rabbit but not human PKR in yeast 
 
(A) Multiple sequence alignment of MYXV-Lu M156, VACV K3, and human (h) eIF2α. 
Conserved residues are highlighted in yellow (100% conservation) or purple (identical with 
M156). The methionine encoded by the putative start codon of the predominant M156 isoform is 
shown in red. An asterisk indicates L98 in MYXV-Lu M156. Plasmids encoding VACV K3, 
MYXV M156 or empty vector under the control of a yeast GAL-CYC1 hybrid promoter were 
transformed into isogenic yeast strains, which have either empty vector (control) (B), human 
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PKR (C), or E. rabbit PKR (D) stably integrated at the LEU2 locus under the control of the 
GAL-CYC1 promoter. Transformants were colony purified and grown under inducing conditions 
at 30 ˚C for 4 d. Results shown are representative of 4 independent transformants for each 
plasmid. (E) Transformants described above were grown in liquid SC-Gal medium for 4 hours to 
induce expression. Whole cell protein extracts were obtained from equal numbers of cells and 
subjected to Western blot analyses. The blots were probed with phospho-specific antibodies 
against Ser51 eIF2α (eIF2α-P), then stripped and probed with polyclonal antiserum against total 
eIF2α.  
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Figure 3.2 Species-specific inhibition of rabbit PKR by M156 
 
  
 
(A) Human HeLa-PKRkd cells were transfected with expression vectors for luciferase 
(0.05 µg), MYXV M156R (0.4 µg) and PKR (0.2 µg) from the indicated mammalian species. 
Luciferase light units were normalized to PKR-only transfected cells to obtain relative luciferase 
activities. Constant amounts (0.1 µg) of human PKR or E. rabbit PKR were cotransfected with 
increasing amounts of M156R (B) or M029L (C) and relative luciferase activities are shown. 
Experiments were performed in triplicate and the results are representative of three independent 
experiments. Error bars indicate SD.  
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Figure 3.3 Human PKR but not rabbit PKR suppresses MYXV replication 
 
(A) Control and congenic HeLa-PKRkd HeLa cell lines that were stably transfected with  
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vector, human PKR, or E. rabbit PKR were infected with VC-R2 [VACV∆E3L(EGFP- 
d2)/∆K3L] or MYXV-EGFP at MOI of 0.1 or 1, respectively. Representative images taken 48 
hpi at 100x magnification are shown. EGFP levels in the two viruses cannot be compared 
directly, because in VC-R2 a destabilized EGFPd2 is driven by the natural E3L promoter, 
whereas in MYXV unmodified EGFP is driven by a synthetic early-late poxvirus promoter. (B) 
Indicated HeLa cell lines were infected with VC-R2 or MYXV-EGFP at an MOI of 0.1 or 1, 
respectively. Viruses were collected at 0, 12, 24, 48 and 72 hpi and titered on RK13 cells, which 
stably express VACV E3 and K3. (C) Total protein lysates were collected from mock (-), VC-R2 
or MYXV-EGFP-infected HeLa cells at 8 hpi to measure phosphorylated and total eIF2α by 
Western blot analyses. Lysates shown were run on the same gel in a different order and lanes 
were reordered for clarity (Fig. 3.12 shows original).  
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Figure 3.4 Deletion of M156R further attenuates MYXV that lacks M029L 
 
 
RK13 cells (RK13-WT) and RK13 cells stably expressing E3 and K3 (RK13+E3L+K3L) 
were infected with MYXV-EGFP (WT), MYXV-M029LKO or MYXV-M029LKOM156RKO at a 
MOI of 5. (A) Fluorescent images were taken at 48 hpi at 100x magnification. (B) Viruses were 
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collected at 0, 12, 24 and 48 hpi and titered on RK13+E3L+K3L cells. Error bars indicate SD 
(n=2). (C) Total protein lysates were collected at 4 and 24 hpi to monitor expression of MYXV 
early (M156 and M-T7) and late (M130) proteins. β-actin was included as loading control.  
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Figure 3.5 A naturally occurring M156R mutant lost its ability to inhibit PKR 
 
 
(A) Crystal structure of the PKR-eIF2α complex. The residue highlighted in pink in the 
structure of eIF2α corresponds to Leu-98 in M156. Plasmids encoding empty vector, M156, or 
M156-L98P under the control of a yeast GAL-CYC1 hybrid promoter were transformed into 
isogenic vector (B) or E. rabbit PKR (C) containing yeast strains. Colony-purified transformants 
were grown under inducing conditions at 30 ºC for 4 d. (D) Transformants were grown in liquid 
SC-Gal medium for 4 h to induce expression. Lysates were subjected to Western blot analysis for 
phosphorylated and total eIF2α. (E) HeLa-PKRkd cells were transfected with expression vectors 
for luciferase (0.05 µg), E. rabbit PKR (0.1 µg) and increasing amounts of M156R or M156R-
L98P. After 48 h, luciferase activities were determined and normalized to control transfections 
lacking PKR inhibitors to obtain relative luciferase activities. (Inset) HeLa-PKRkd cells were 
transiently transfected with 3 µg of vector, M156R or M156R-L98P plasmids. Total protein 
lysates were collected 48 hours after transfection to monitor M156 and β−actin expression. All 
samples were run on the same gel and lanes were spliced together (line) for clarity. (F and G) 
RK13 cells were infected with MYXV-M029LKO, MYXV-M029LKOM156RKO, MYXV-
M029LKOM156RKOM156Rrevertant(rev) and MYXV-M029LKOM156RKOM156R-L98P (MOI of 5). 
Fluorescent images were taken at 24 hpi (F) and virus titers were measured 0 and 48 hpi (G).  
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 Supporting Information 
 SI Materials and Methods 
 
 Plasmids, Yeast strains and Cell Lines 
PKR and viral genes were cloned into the pSG5 vector (Stratagene) for transient 
expression in mammalian cells. European rabbit (Oryctolagus cuniculus) PKR was cloned from 
spleen total RNA from a New Zealand white rabbit. The obtained PKR (accession number: 
KT272867) differed from NP_001075682 at 8 amino acid positions but was identical to 
ENSOCUT00000007225 (Ensmbl database). Sheep (Ovis aries) PKR (KT272868) was cloned 
from MDOK cells (ATCC CRL-1633). Three identical cDNA were obtained that differ from the 
predicted sheep PKR (XM_004007300.1) at six synonymous nucleotide positions. Rat (Rattus 
norvegicus) PKR was cloned from rat-1 cells and is identical to XM_008764426.1. Syrian 
hamster (Mesocricetus auratus) PKR was cloned from BHK-21 cells (ATCC CCL-10) and is 
identical to NM_001281945.1. Chinese hamster (Cricetulus griseus) PKR (KT272869) was 
cloned from CHO cells. Guinea pig (Cavia porcellus) PKR (KT272870) was cloned from 104C1 
cells (ATCC CRL-1405) and is identical to the predicted Genbank sequence XM_003472904.2. 
Cloning of knock-down resistant human PKR and mouse PKR was described (1). VACV K3L, 
M029L and M156R short and long forms were cloned into pSG5. The M156R-L98P mutation 
was generated by site-directed mutagenesis PCR using the PfuUltra High-Fidelity DNA 
polymerase (Invitrogen). PCR was performed using the pSG5-M156R-short construct as the 
template with primers containing the leucine-to-proline mutation (CTG to CCG) flanked by 15 
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nucleotides identical to the template up- and downstream of the mutation. All ORFs were 
sequenced to confirm correct sequences. 
Generation of yeast strains stably transformed with empty vector (J673) or human PKR 
(J983) under the control of a yeast GAL-CYC1 hybrid promoter was described (18). A yeast 
strain stably transformed with E. rabbit PKR (O8) was generated using the same methods. 
VACV K3L and M156R were cloned into the vector pYX113 (R&D systems), which contains 
the GAL-CYC1 hybrid promoter and the selectable marker URA3. HeLa-PKRkd cells and 
control HeLa cells were kindly provided by Charles Samuel (24). RK13 cells were kindly 
provided by Bernard Moss. To generate HeLa-PKRkd cells that express PKR, a plasmid was 
constructed that contains the human PKR promoter as described (19) (nucleotide positions -412 
to + 97 relative to the transcriptional start site) followed by the intron of the rabbit β-globin gene 
from pSG5 and a multiple cloning site followed by a sequence encoding two FLAG tags and 
inserted into the pEGFP-N1 (Clontech) in place of the CMV promoter/enhancer, the multiple 
cloning site and the EGFP open reading frame. Knock-down resistant human PKR and E. rabbit 
PKR were cloned into this vector with the FLAG tags at their C-termini. HeLa-PKRkd cells were 
transfected using GenJet-HeLa (SignaGen Laboratories) according to the manufacturer’s 
instructions. Cells were trypsinized 48 h after transfection and cultured in the presence of 1µg/ml 
Geneticin (Invitrogen) for 14 days. To select clones, cells were seeded on 96-well plates at the 
density of 0.3 and 1 cell/well until single colonies appeared. Clones were then amplified and 
proteins were isolated to detect the expression of transfected PKR with an anti-FLAG tag 
antibody (ABM) and the absence of endogenous human PKR with the monoclonal anti-human 
PKR antibody 71/10. A human PKR reconstituted clone (HeLa-hs14) that showed comparable 
PKR expression level as the endogenous human PKR in HeLa control cells was selected and 
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amplified. A E. rabbit PKR expressing clone that showed PKR expression levels comparable to 
that of human PKR in HeLa-hs14, as determined with the anti-FLAG tag antibody, was used for 
subsequent experiments. For transfections, plasmids were prepared using NucleoBond Xtra Midi 
Endotoxin Free (Macherey-Nagel). 
 5’ RACE PCR 
E. rabbit RK13 cells were infected with MYXV-EGFP at a MOI of 1. Total RNA was 
collected with TRIzol reagent (Invitrogen) at 4, 12 and 24 hours postinfection. RACE PCR was 
performed with the GeneRacer Core Kit (Invitrogen) according to the manufacturer’s instruction. 
Briefly, two rounds of PCR were conducted to amplify the 5’ end of M156R cDNA using 5’ 
adaptor primers provided in the kit and M156R-specific reverse primers. The second-round PCR 
products were cloned into the TOPO-TA vector (Invitrogen) and 6 colonies from each time point 
were randomly chosen for sequencing. 
 Yeast Growth and eIF2α Phosphorylation Assays 
Yeast transformation was performed using the Lithium Acetate/PEG method. J673, J983 
and O8 strains were transformed with empty vector pYX113, K3 or M156 expressing plasmids. 
For each transformation, four independent clones were picked and colony-purified on SD plates. 
Purified colonies were then streaked on either glucose (non-inducing conditions) or galactose 
containing medium [synthetic complete medium containing 2% (wt/vol) galactose and all amino 
acids without uracil, inducing conditions], and grown for 4 d at 30 ˚C. For Western blot analyses 
of yeast proteins, all transformants were grown to saturation in SD medium overnight. The start 
culture was then diluted 1:40 in SD medium on the second day and grown to OD600 = 0.6 and 
subsequently shifted to SC-Gal medium to induce expression. After 4 h, ODs of the cultures 
were obtained and cultures were diluted accordingly in water to reach the same ODs. Equal 
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amounts of cells for each sample were lysed using the trichloroacetic acid (TCA) method. 
Samples were mixed with loading buffer with reducing agent and neutralized with 1M Tris-base. 
Proteins were fractionated on 10% (vol/vol) SDS-PAGE gels and then transferred to PVDF 
membranes (Millipore). Membranes were incubated with anti-phospho-S51 eIF2α (Bio-Source 
International) and then stripped and re-probed with anti-total eIF2α antibodies (25). Enhanced 
chemiluminescence was detected with a Kodak image system. 
 Luciferase Assay 
5 x 104 HeLa-PKRkd cells were seeded in 24-well plates 1 d before transfection. For each 
transfection firefly luciferase (pGL3promoter, 0.05 µg, Promega), and pSG5 plasmids encoding 
PKR (0.3 µg), M156, M156-L98P or M029 (0.4 µg) were transfected using GenJet-HeLa. For 
titration experiments, amounts of transfected plasmids are indicated in the figures. For controls, 
empty pSG5 vector was transfected using the same amount. Each transfection was conducted in 
triplicate. After 48 hours, cell lysates were harvested using mammalian lysis buffer (Goldbio) 
and luciferase activity was determined using luciferase detection reagents (Promega) in a 
luminometer (Berthold). Each experiment was performed at least three times and representative 
experiments are shown in the results. Error bars represent the standard deviations of three 
independent transfections. 
 Infection Assays and Western blot Analyses 
RK13 cells were infected with mock (PBS) or MYXV-EGFP (Lu strain) at an MOI of 10. 
Proteins were collected at the indicated time points using an Nonidet P-40 lysis buffer (50mM 
Tris, 150mM NaCl, 1% Nonidet P-40, and proteinase inhibitor cocktail, Roche). Protein 
concentrations were determined by the Bradford assay (BioRad). Protein samples were separated 
112 
on 10% (vol/vol) SDS-PAGE gels and transferred to PVDF membranes (GE Healthcare) using a 
methanol-based wet transfer apparatus (BioRad). Membranes were blocked with 5% (wt/vol) 
non-fat milk or 5% BSA when detecting eIF2α-P in TBST buffer (20mM Tris, 150mM NaCl 
and 0.1% Tween-20 pH7.6) for 3 hours at 4°C and then incubated overnight with anti-serum 
raised against M156 (27) at 4˚C with rocking, and then stripped and re-probed with anti-serum 
against M-T7 (28), M130 (29), and an antibody against β-actin (Sigma-Aldrich). After washing, 
membranes were incubated with goat-anti-rabbit or goat-anti-mouse secondary antibodies 
(1:30,000) in TBST containing 5% (wt/vol) non-fat milk for 1 h at room temperature with 
agitation followed by TBST washing 4 times for 20 minutes each. Proteins were detected with 
Proto-Glo ECL (National Diagnostics) and images were taken with a Kodak image system. 
HeLa-control, HeLa-PKRkd, HeLa-PKRkd+vector, HeLa-PKRkd+hPKR, and HeLa-
PKRkd+E.rabbit PKR cells were seeded into six-well plates and confluent monolayers (1x106 cells) 
were mock infected with PBS or infected with VC-R2 and MYXV-EGFP at an MOI of 0.1 and 
1, respectively. Fluorescent pictures were taken with an inverted fluorescent microscope (Leica) 
at 48 hpi and viruses were collected at 0, 24, 48 and 72 hpi and were titered in RK13 cells that 
stably express E3 and K3 (21). For eIF2α phosphorylation assays, the previously described 
PKR-expressing cells were infected with VC-R2 and MYXV-EGFP at an MOI of 5. Total 
protein lysates were collected at 8 hpi with 1% SDS in PBS and fractionated on 10% (vol/vol) 
SDS-PAGE gels. Western blot analyses were performed as described above. Primary antibodies 
detecting S51 phospho-eIF2α (Bio-Source International) and total eIF2α (Santa Cruz) were 
diluted 1:10,000 and 1:1000, respectively, in TBST. 
 Construction of Recombinant Viruses 
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The generation of VC-R2, a vaccinia virus Copenhagen strain that lacks E3L and K3L 
(VACVΔK3L/ΔE3L) and carries a destabilized EGFP gene in the E3L locus, and MYXV-EGFP in 
which a synthetic vaccinia virus early/late promoter-driven EGFP cassette was inserted into the 
intergenic region in the M135-136 locus, were described previously (20, 26). The strategy to 
generate recombinant myxoma viruses is illustrated in Fig. S5. To create a M156R deficient 
virus, a recombinant plasmid was first constructed in which a poxvirus synthetic early/late 
promoter-driven mRFP is flanked by sequences 5’ and 3’ of the M156R locus, which contain 
partial sequences of M154L (5’), M008.1L (3’) and intergenic sequences (both 5’ and 3’). 
MYXV-M029LKOM156RKO was generated by infecting RK13+E3L+K3L cells with MYXV-
EGFP-M029LKO (Lu), followed by transfection of the recombinant plasmid. Multiple rounds of 
foci purification were performed with the same cell line using mRFP as selection marker. The 
recombinant locus was then PCR-amplified from the viral clone and sequenced to confirm 
successful recombination. To generate MYXV-M029LKOM156RKOM156Rrev and MYXV-
M029LKOM156RKOM156R-L98P recombinant viruses, RK13+E3L+K3L cells were infected 
with MYXV-M029LKOM156RKO followed by transfection of recombinant plasmids in which the 
original M156 or the M156-L98P coding sequences were flanked by 5’ and 3‘ arms described 
above. Multiple rounds of foci-purification were performed in RK13+E3L+K3L cells based on 
the absence of mRFP expression. In all recombinant MYXV, the M156R locus as well as the 
region comprising the partially duplicated M156R copy in the 5’ region was PCR-amplified and 
sequenced to confirm successful integration and exclude unwanted mutations. 
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Figure 3.6 (S1) Identification of the major M156 transcription start sites (TSSs) 
 
(A) Multiple sequence alignment of human eIF2α and viral eIF2α homologs from 
MYXV-Lu, rabbit fibroma virus, MYXV-MSW, VACV and Rana catesbeiana virus Z. 
Conserved residues are highlighted in yellow (100% conservation) or purple (identical with 
MYXV-Lu). An asterisk indicates L98 in MYXV-Lu M156. (B) Illustration of the observed 
TSSs for M156R. The genomic composition of the 5’ end of M156R locus is indicated with red 
arrows denoting the presence of ATG codons. Numbers indicate relative nucleotide positions 
with respect to the identified start codon. Blue bars represent observed TSSs at any of the 3 time 
points. The height of each bar is proportional to the number of times each particular site TSS was 
observed. A predicted poxvirus early promoter motif is highlighted in the light green box. (C) 5’-
RACE PCR was performed with RNA collected from MYXV-infected RK13 cells at 4, 12 and 
24 hpi. Total PCR products were cloned and sequenced. (D) M156 is an early protein. RK13 
cells were left uninfected (mock, lane 1) or infected with MYXV with an MOI of 10. Total 
protein was collected at indicated time points (lane 2-6). Short and long forms of M156R were 
transiently transfected and total protein was collected 24 hours later. All protein samples were 
separated on SDS-PAGE and subjected to Western blotting analyses. The membrane was first 
probed with an anti-M156 antibody, then consecutively stripped and probed for M-T7 (early 
gene), M130 (late gene), and β-actin (loading control).  
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Figure 3.7 (S2) Sequence alignment of the 5' RACE PCR products 
 
 
European rabbit RK13 cells were infected with MYXV-Lu and the total RNA was 
collected at indicated time points. The 5’ RACE PCRs were performed and the PCR products 
were cloned and sequenced. The 5’ ends of the predicted long (126 bp) and short (45 bp) forms 
of M156R were aligned with sequences of the 5’ RACE PCR clones by the program MegAlign 
(DNASTAR).  
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Figure 3.8 (S3) M156 but not M011, M013, M130 or MT-5 inhibits E. rabbit PKR 
 
 
Human HeLa-PKRkd cells were transfected with expression vectors for luciferase (0.05 
µg), human, or E. rabbit PKR (0.2 µg) and myxoma virus M156, M156-L98P, M011, M013, 
M130 or MT-5 (0.4 µg each). pSG5 and pcDNA3.1 serve as empty vector controls. Luciferase 
light units were normalized to cells transfected only with PKR and pSG5 to obtain relative 
luciferase activities. Error bars indicate SD.  
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Figure 3.9 (S4) PKR expression in HeLa cells and derived cell lines 
 
HeLa-PKRkd cells were stably transfected with vector, human (h) or E. rabbit (r) PKR 
under the control of the human PKR promoter. The human PKR-expressing clone h14 (lane 3) 
showed PKR expression comparable to that in HeLa control cells (lane 2) using an anti-human 
PKR antibody. Untransfected HeLa-PKRkd cells are shown in lanes 1 and 4. Clone h14 was used 
to identify rabbit PKR-expressing clone r15, which showed comparable expression levels using 
an anti-FLAG tag antibody (lanes 5 and 6). After stripping, membranes were re-probed with anti-
β-actin antibodies.  
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Figure 3.10 (S5) Construction of recombinant myxoma virus strains 
 
The M156 coding sequence was partially replaced by a DNA cassette containing a 
monomeric red fluorescent protein (mRFP) encoding gene. The genomic region surrounding the 
M156R locus is shown in A. The region duplicated in the inverted terminal repeat is indicated. 
(B) The recombination plasmid to delete M156R contains a part of the M154L gene, the 
intergenic region between M154L and M156R, part of the M156R sequence, a poxvirus synthetic 
early/late (sE/L) promoter followed by the mRFP gene, followed by a part of the M156R 
sequence, the intergenic region between M156R and M008.1L and a part of M008.1L. To 
generate revertant M156R- (MYXV-M029LKO/M156RKOM156Rrev) and M156R-L98P- (MYXV-
M029LKO/M156RKOM156R-L98P) containing strains, the constructs shown in C and D, 
respectively, were used.  
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Figure 3.11 (S6) M029-A17V does not show altered PKR inhibition 
 
Constant amounts of human or E. rabbit PKR (0.1 µg) and firefly luciferase (0.05 µg) 
were cotransfected with increasing amounts of M029L or M029L-A17V. Relative luciferase 
activities are shown. Experiments were performed in triplicate and the results are representative 
of three independent experiments. Error bars indicate SD.  
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Figure 3.12 (S7) Original Western blot modified for Fig. 3B 
 
(A) Original Western blots for phosphorylated and total eIF2α in total protein lysates 
collected from mock (-) or MYXV-EGFP (+) infected HeLa cells at 8 hpi. For clarity, the lanes 
that show eIF2α from HeLa-PKRkd (light blue bar) and HeLa control cells (green bar) were 
switched to generate the figure shown in B and Fig. 3B.  
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Chapter 4 - Host species-specific inhibition of rabbit PKR by 
leporipoxvirus pseudosubstrate inhibitors  
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 Abstract 
The introduction of myxoma virus (MYXV) into European rabbits in Australia has 
provided us with one of the best documented examples to explore how a virus pathogen evolves 
to adapt to a new host species. Therefore, for years, the studies that characterize MYXV proteins 
and their interactions with the host immune systems have been using non-rabbit cell lines or cell 
lines directly derived from European rabbits (Oryctolagus cuniculus). However, the interactions 
between MYXV and its natural hosts American Sylvilagus rabbits have been largely ignored. 
Oryctolagus and Sylvilagus rabbits shared their last ancestor about 10 million years ago (30). 
Interestingly, infections of MYXV in Sylvilagus rabbits are completely non-lethal in adult 
animals, in contrast to the extremely high fatality rate caused by MYXV in European rabbits. 
The reason why a virus displays such a dramatic difference in virulence in two intermediately 
related species likely lies in how the immune responses of these two rabbit species differ during 
MYXV infection. In order to address a potential molecular explanation for the observed 
difference in virulence, we have compared the interactions of the host antiviral protein kinase R 
(PKR) from European rabbits and brush rabbits (Sylvilagus bachmani) with the MYXV PKR 
inhibitor M156R and its ortholog from rabbit fibroma virus R156R, a closely related 
leporipoxvirus. The transfection-based luciferase assay revealed that brush rabbit PKR is more 
sensitive to M156R inhibition than European rabbit PKR, that European rabbit PKR is 
completely resistant to R156R inhibition whereas brush rabbit PKR is highly sensitive. 
Additionally, NF-κB reporter assays indicate that this differential PKR sensitivity may contribute 
to variable expression of NF-κB-regulated pro-inflammatory cytokines, which may result in the 
high virulence of MYXV in European rabbits, but not in brush rabbits. We also identified the 
residues in European rabbit and brush rabbit PKR that are responsible for their sensitivity to 
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M156R and R156R inhibition. Our results indicate that PKR from European rabbits and brush 
rabbits exhibit distinctive sensitivities to MYXV M156R due to their different compositions at 
the helix αG region, and these differences may contribute to the difference of MYXV virulence 
observed in two different rabbit species. 
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 Introduction 
The biological control of European rabbits in Australia with MYXV is one of the best-
documented examples for virus adaptation and evolution of virulence after a virus “jumps” into a 
new host species. The fast attenuation of MYXV and the concomitant selection of genetically 
somewhat resistant rabbits provides us with a classical demonstration of natural selection in both 
the virus and the host. MYXV belongs to the genus leporipoxvirus, which also includes rabbit 
fibroma virus, squirrel fibroma virus and hare fibroma virus (1). Leporipoxvirus members often 
display very narrow host range, infecting only leporids or squirrels (reviewed in (2) and (3)). In 
their natural hosts, leporipoxviruses usually cause benign and localized skin fibromas that are 
non-lethal (reviewed in (4)). For example, in the natural hosts of MYXV, the American tapeti or 
brush rabbits (Sylvilagus rabbits), the virus causes innocuous cutaneous fibromas that are usually 
restricted to the site of inoculation. The infection typically persists for several weeks but does not 
kill the host unless in very young rabbits (1). In contrast, in European rabbits (Oryctolagus 
cuniculus), MYXV causes a lethal systemic infection termed myxomatosis with a case fatality 
rate of close to 100% in naïve rabbits (5). This dramatic virulence difference of the same virus 
displayed in two intermediately related species provides a great model to explore the 
determinants for poxvirus virulence at the molecular level.  
In nature, MYXV is predominantly passively transmitted by biting arthropods, in which 
the virus does not replicate. Therefore, successful transmission is dependent on the titer of virus 
propagated in the virus-induced fibromas (6). Highly attenuated virus strains fail to replicate to a 
high titer before being cleared by the host’s immune system, while highly virulent strains often 
kill the host before efficient dissemination of the virus occurs, which prevents virus transmission 
to the next host (7). Hence in Australia, MYXV strains with moderate virulence often quickly 
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predominate the field after each release of the highly virulent strains, suggesting that MYXV 
evolved to attenuate in European rabbits to achieve optimal transmission.  
There are two geographically distinct clades of MYXV. The South American MYXV 
clade includes strains that naturally infect American tapeti rabbits (Sylvilagus brasiliensis) 
localized in the South America. On the other hand, the Californian MYXV clade includes those 
that are (including the MSW strain and the MSD strain) found in North America, which naturally 
infect brush rabbits (Sylvilagus bachmani). The Californian MYXV strains are more virulent 
than the SLS and the Lausanne strains in European rabbits, exhibited by the ability of the virus to 
kill the rabbits before clinical symptoms of myxomatosis appear (8-10).  
Rabbit fibroma virus (RFV, also known as Shope fibroma virus) is another member of 
the genus leporipoxvirus, which naturally infects Eastern cottontails (Sylvilagus floridanus) that 
are widely distributed throughout the USA (8, 11). In its natural host, RFV causes cutaneous 
fibroma that are restricted to the site of inoculation and the infection can last for months before 
being cleared completely by the host’s immune system (12). Recovered rabbits are protected 
from reinfection (12). Interestingly, in contrast to the drastic virulence difference displayed by 
MYXV between its natural Sylvilagus rabbit hosts and European rabbits, RFV causes very 
similar, benign and transient tumors in Eastern cottontails and European rabbits without inducing 
any generalized infection like myxomatosis (reviewed in (13)). In fact, due to the heterologous 
protection provided by RFV for myxomatosis in European rabbits, the virus was used 
extensively as a vaccine strain in farmed and wild European rabbits in France before attenuated 
MYXV strains were introduced for vaccination (reviewed in (14)).  
The genomes of Lu MYXV, MSW MYXV and RFV have been fully sequenced and 
published (10, 12, 15). The MSW MYXV is more closely related to Lu MYXV than to RFV, but 
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has an expanded genome size compared to the Lu strain (164kb compared to 161kb of MYXV-
Lu), mainly due to the extension of the inverted terminal repeat region. This region contains 
mostly host range and virulence genes and is more variable than the central region of the 
genome. Truncated genes are also identified in MSW MYXV compared to those of Lu MYXV. 
This includes two genes: M008.1L/R and M152R, which are known to be major virulence factors 
previously characterized in European rabbits (16-18). The RFV genome, on the other hand, is 
smaller than both MYXV strains with only 159 kb. Compared to MYXV-Lu, a cluster of genes 
close to the end of the RFV genome are missing or are truncated in the RFV genome, such as 
M000.5L/R, M008.1L/R and M152R (19).  
Both MSW MYXV and RFV contain a K3L/M156R ortholog, which are putative PKR 
inhibitors. Compared to MYXV-Lu M156R characterized in the previous chapter, both MSW 
M156R and RFV R156R lack the extended N-terminus, displaying 53% and 77% sequence 
identity at the protein level with the Lu M156R, respectively (16-18). Moreover, both MSW 
M156R and RFV R156R are duplicated in the inverted repeat region while the MYXV-Lu 
contains only one complete copy of this gene in its genome. However, it is worth noting that the 
3’ end of the M156R coding sequence is partly duplicated (109 bp) in the 5’ ITR region in the 
MYXV-Lu (15). It is unclear, however, whether or not the copy number of M156R and R156R 
influences the virus virulence or host range. 
This chapter aims to expand the analysis of PKR’s interactions with pseudosubstrate 
inhibitors to other leporipoxviruses including RFV and MSW MYXV. We thoroughly explored 
the sensitivities of PKR from European rabbit and brush rabbit to selected leporipoxvirus 
K3L/M156R orthologs. In addition, we unveiled a potential connection between the activity of 
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PKR and NF-κB-regulated protein expression, which may contribute to the pathogenesis of 
myxomatosis in European rabbits.   
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 Materials and Methods 
 Plasmids and cell lines 
Cloning of European rabbit PKR and MYXV M156R was described in the previous 
chapter (Chapter 3). Brush rabbit PKR was cloned from total RNA collected from muscle and 
connective tissues of the paws of brush rabbits, which were kindly provided by the Riparin Brush 
Rabbit Recovery project. RFV R156R, MSW MYXV M156R were cloned into the pSG5 vector 
for expression in mammalian cells. The NF-κB reporter plasmid contains a firefly luciferase 
gene driven by six NF-κB binding sites followed by a minimal beta-globin promoter (28). The 
renilla luciferase vector was driven by an SV40 promoter. The PKRkd HeLa cell line was 
generated by stably transfecting HeLa cells with shRNA and was kindly provided by Charles E. 
Samuel (Chapter 3). The European rabbit and brush rabbit triple-mutant PKR containing the 
swapped helix αG region were generated by site-directed mutagenesis PCR using the PfuUltra 
High-Fidelity DNA polymerase (Invitrogen). PCR was performed using pSG5-European rabbit 
PKR and pSG5-brush rabbit PKR as the templates with primers containing the designed 
mutations flanked by 15 nucleotides identical to the template up- and downstream of the 
mutation. All open reading frames were sequenced to confirm correct sequences. 
HeLa-PKRkd cells were cultured in DMEM medium supplemented with 5% FBS and 
50µg/ml of gentamycin and were maintained at 37˚C with 5% CO2. 
 Generation of hyperactive M156R 
The hyperactive M156R was identified by transforming a European rabbit PKR 
expressing yeast strain with M156R-containg plasmids that were randomly mutagenized with a 
low-fidelity polymerase. The mutagenesis generated a library of approximately 85,000 clones 
133 
with a calculated mutation rate of 57%. 4,000 transformants containing the mutagenized M156R 
were picked and analyzed by transforming them into the yeast strain that has chromosomally 
integrated European rabbit PKR driven by a galactose-inducible promoter described in the 
previous chapter (Chapter 3). The transformants that showed better growth were selected through 
replica printing under inducing conditions. Plasmids from 50 yeast colonies were transformed 
into E.coli and sequenced after plasmid preparations. Mutants confirmed by sequencing were 
further re-transformed into yeast for confirmation of better PKR inhibition. Additionally, the 
mutations were introduced into pSG5-M156R to perform luciferase assays. 
 Luciferase assay and NF-kB activity assay 
5 x104 HeLa-PKRkd cells were seeded in 24-well plates one day before transfection. For 
each transfection firefly luciferase (pGL3promoter, 50 ng, Promega) and pSG5 plasmids 
encoding European rabbit or brush rabbit PKR (200 ng), M156R, R156R, MSW M156R, 
M156R-K48Q (400 ng) were transfected using GenJet-HeLa (SignaGen). For controls, empty 
pSG5 vector was transfected using the same amount. Each transfection was conducted in 
triplicate. For NF-κB activity assays, the plasmids encoding NF-κB-luc (50ng) and SV40-luc 
were co-transfected with the above mentioned PKR plasmids, M156 and a renilla luciferase 
driven by the TK promoter as internal controls. After 48 hours, cell lysates were harvested using 
mammalian lysis buffer (Goldbio) and luciferase activity was determined using luciferase 
detection reagents (Promega) in a luminometer (Berthold). Each experiment was performed at 
least three times independently and representative results are shown. Error bars represent the 
standard deviations of three replicate transfections. 
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 Western blot analyses 
Proteins were collected at the indicated time points using an NP-40 lysis buffer (50mM 
Tris, 150mM NaCl, 1% NP-40 and proteinase inhibitor cocktail, Roche). Protein concentrations 
were determined by the Bradford assay (BioRad). Protein samples were separated on 10% SDS-
PAGE gels and transferred to PVDF membranes (GE Healthcare) using a methanol-based wet 
transfer apparatus (BioRad). Membranes were blocked with 5% non-fat milk in TBST buffer 
(20mM Tris, 150mM NaCl and 0.1% Tween-20 pH7.6) for 3 hours at 4°C and then incubated 
overnight with monoclonal anti-FLAG antibody at 4˚C with rocking, and then stripped and re-
probed with antibody for β-actin (Sigma-Aldrich). After washing, membranes were incubated 
with goat-anti-rabbit or goat-anti-mouse secondary antibodies (1:30,000) in TBST containing 5% 
non-fat milk for 1 hour at room temperature with agitation followed by TBST washing 4 times 
for 20 minutes each. Proteins were detected with Proto-Glo ECL (National Diagnostics) and 
images were taken with a Kodak image system. 
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 Results 
 M156R inhibits PKR from the natural host of MYXV with higher efficiency 
Our previous results showed that MYXV M156R specifically inhibited European rabbit 
PKR but not PKR from non-rabbit mammals (Chapter 3). Considering that the natural hosts of 
MYXV are Sylvilagus rabbits, including the American tapeti and brush rabbits, we investigated 
if MYXV M156R shows differential inhibition of PKR from different rabbit species. We cloned 
and sequenced PKR from muscular tissues of three brush rabbits (Sylvilagus bachmani riparius). 
A sequence alignment revealed that European rabbit and brush rabbit PKR display 93% 
sequence identity at the protein level (Fig. 4.1). Discrepancies between the two PKRs are found 
throughout the protein sequence including the dsRNA binding domains, linker region and the 
kinase domain (Fig. 4.1). We next analyzed the PKR inhibitory activity of M156R on both brush 
rabbit and European rabbit PKR in the previously described cell culture-based luciferase assay. 
Human HeLa cells, in which endogenous PKR expression was stably knocked-down by shRNA, 
designated as HeLa-PKRkd cells, were co-transfected with firefly luciferase, European or brush 
rabbit PKR and M156R or an empty vector as control. Luciferase activities were monitored 48 
hours after transfection and normalized to that in PKR-only transfected cells (control) for better 
comparison. Consistent with the previous observation, co-transfection of Lu-M156R resulted in 
an increase of luciferase activity compared to European rabbit PKR-only transfected cells, 
indicating European rabbit PKR is sensitive to Lu-M156R inhibition (Fig. 4.2). Interestingly, we 
observed that co-transfection of brush rabbit PKR and Lu-M156R led to a statistically significant 
increase of luciferase activity compared to that caused by the co-transfection of European rabbit 
PKR and Lu-M156R (Fig. 4.2). This result showed that PKR from brush rabbit was more 
sensitive to M156R inhibition than European rabbit PKR. To investigate whether this difference 
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is specific to the inhibition by Lu-M156R, we also examined the sensitivity of both PKR to K3L, 
the M156R ortholog from VACV, whose natural host is unknown, but is known to be able to 
infect many different species including rabbits. K3L was able to inhibit PKR-mediated luciferase 
reduction in both European and brush rabbit PKR-transfected cells to comparable levels, 
suggesting both PKR are sensitive to K3L (Fig. 4.3). This result indicates that the difference in 
PKR sensitivity that we observed was specific to Lu-M156R. We also tested if the difference in 
PKR sensitivity was due to different levels of PKR expression between the two species by 
Western blot analyses and found that in HeLa-PKRkd cells, Flag-tagged European rabbit PKR 
and brush rabbit PKR were expressed at comparable levels (Fig. 4.4). 
To further confirm the differential sensitivity of PKR to M156R inhibition between 
European rabbit and brush rabbit PKR, we utilized a dual luciferase assay in which the firefly 
luciferase expression was driven by a full-length mouse ATF4 (Activating Transcription Factor 4) 
mRNA leader sequence (designated ATF4-luc fusion), while the renilla luciferase expression is 
controlled by a non-inducible TK promoter (20). In eukaryotic cells, translational up-regulation 
of ATF4 is induced as a result of eIF2α phosphorylation during ER (endoplasmic reticulum) 
stress. Therefore, in this assay, the firefly luciferase activity can be used to indirectly quantify 
eIF2α phosphorylation (20). Using this assay, we compared the ATF4-luc fusion expression 
when European rabbit PKR or brush rabbit PKR were co-transfected with K3L or Lu-M156R. 
As shown in Fig. 4.5, co-transfection of both K3L and Lu-M156R reduced ATF4-luciferase 
expression compared to PKR only-transfected cells, indicating alleviated eIF2α phosphorylation 
when PKR was co-transfected with viral inhibitors. Co-transfection of K3L diminished ATF4-
luciferase expression in European rabbit or brush rabbit PKR-transfected cells to comparable 
levels, suggesting the two PKRs are comparably sensitive to K3L inhibition. In contrast, co-
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transfection of M156R resulted in approximately 70% reduction of luciferase activity in 
European rabbit PKR-transfected cells, but led to an approximately 98% reduction of luciferase 
activity reduction in brush rabbit PKR-transfected cells. This indicates that MYXV M156R can 
relieve brush rabbit PKR-mediated eIF2α phosphorylation more efficiently than that mediated by 
European rabbit PKR. This result confirmed our previous observation in the single-luciferase 
assay that brush rabbit PKR was more sensitive to M156R inhibition than European rabbit PKR.  
We also examined PKR inhibition by MYXV-MSW M156R (MSW-M156R) and found 
comparable inhibition of European PKR as mediated by MYXV-Lu M156R (Lu-M156R) (Fig. 
4.6). Both Lu-M156R and MSW-M156R showed comparable capability in restoring PKR-
mediated translational suppression in both European rabbit and brush rabbit PKR-transfected 
cells (Fig. 4.6). This results showed European rabbit PKR, as well as brush rabbit PKR, were 
inhibited by Lu-M156R and MSW-M156R comparably. Therefore, we kept using the Lu-M156R, 
designated M156R, in the next tests.  
All these results confirmed that MYXV M156R inhibited PKR from the natural host of 
the virus with higher efficiency.  
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 RFV R156R inhibits brush rabbit but not E. rabbit PKR 
To further explore the species-specific PKR inhibition by leporipoxvirus pseudosubstrate 
inhibitors, we cloned and examined the PKR inhibitory ability of the RFV K3L/M156R 
orthologs, R156R, with European and brush rabbit PKR in the luciferase assay. Both R156R and 
M156R co-transfection with brush rabbit PKR resulted in increased luciferase activities, 
suggesting that brush rabbit PKR was inhibited by both M156R and R156R (Fig. 4.7). 
Surprisingly, the luciferase reduction mediated by European rabbit PKR was not alleviated by 
co-transfection of R156R, but only by co-transfection of M156R as observed previously (Fig. 
4.7). In addition, the two K3L orthologs, M156R and R156R, were expressed at comparable 
levels in HeLa-PKRkd cells as shown by Western blot analyses (Fig. 4.8), suggesting the 
observed difference between M156R and R156R was not due to different levels of protein 
expression. This indicates that RFV R156R inhibited only brush rabbit PKR but not European 
rabbit PKR.  
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The helix αG region is responsible for the differential sensitivity of rabbit PKR to 
M156R and R156R inhibition 
We have discovered that European rabbit and brush rabbit PKR display differential 
sensitivities to leporipoxvirus pseudosubstrate inhibitors M156R and R156R. We next asked 
which amino acids of the two PKR molecules were responsible for these differences. Previous 
results from our lab suggested that single amino acid mutations of residues A488 and E451, 
which reside in the helix αG region on human and mouse PKR, respectively, altered their 
sensitivities to vaccinia virus (VACV) K3L inhibition (21). We thus sought to examine if the 
helix αG regions, which directly contact with eIF2α, as seen in the co-crystal structure of eIF2a 
with human PKR (29), of European rabbit PKR (amino acid residues 483-496) and brush rabbit 
PKR (amino acid residues 482-495) contribute to their sensitivities. Four residues are different 
between European and brush rabbit PKR in the helix αG region (Fig. 4.9 A). We swapped these 
four residues between European rabbit and brush rabbit PKR either as a group or individually 
and tested the mutants’ sensitivities to M156R and R156R. The mutated European and brush 
rabbit PKR with completely swapped helix αG regions were as competent as their wild type 
counterparts in translational reduction of luciferase (Fig. 4.9 B), suggesting their ability to 
phosphorylate eIF2α was not jeopardized by the mutations. Importantly, compared to the wild-
type European rabbit PKR, we observed that the mutant with the brush rabbit PKR helix αG 
region behaved comparably as brush rabbit PKR in terms of PKR sensitivity to M156R and 
R156R (Fig. 4.9 B). The brush rabbit PKR mutant containing helix αG residues from the 
European rabbit PKR, on the other hand, showed reduced sensitivity to M156R and was largely 
resistant to R156R inhibition (Fig. 4.9 B). These results suggest that the helix αG region of both 
rabbit PKR contribute to the observed differences in PKR sensitivity to M156R and R156R.  
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To determine if specific amino acid residues are important for these differences, we next 
swapped amino acids V485, A488, A492 and R496 in European rabbit PKR and their 
corresponding residues in brush rabbit PKR individually and examined their sensitivities to 
M156R and R156R. As summarized in Fig. 4.10, none of the single residue exchanges could 
completely replicate the phenotypic exchange observed with quadruple mutations of all four 
residues, but mutations of residues 485, 488 or 492 in European rabbit PKR and the 
corresponding residues in brush rabbit PKR partly altered their sensitivities. In contrast, 
mutations R496S in European rabbit PKR and S495R in brush rabbit PKR showed no phenotypic 
change compared to the wild type PKRs, indicating this residue may not be involved in the direct 
interaction of PKR with M156R or R156R (Fig. 4.10). We next performed triple amino acid 
mutations that exchanged residues 485/484, 488/487 and 492/491 between the two PKRs, and 
discovered that the swapping of these three residues could completely replicate the phenotypic 
exchange observed with quadruple mutations of both PKRs (Fig. 4.11 and 4.12).  
In conclusion, our findings suggest that the helix αG region, especially the residues 
A485, V488 and A492 in European rabbit PKR and their corresponding residues in brush rabbit 
PKR, are mainly responsible for the differential sensitivity of rabbit PKR to inhibition by 
leporipoxvirus pseudosubstrate inhibitors. 
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 Intermediate PKR inhibition induces strong NF-κB activity 
NF-κB is a central regulator of both innate and adaptive immune responses against viral 
pathogens (reviewed in (22)). Overreaction of NF-κB regulated immune responses may lead to 
pathogenic effects due to aberrant accumulation of pro-inflammatory cytokines resulting in local 
and systemic inflammation (23). Acute inflammation is often observed in dermis, lymph nodes 
or skin lesions in myxoma-infected European rabbits (24). Therefore, the NF-κB-induced pro-
inflammatory cytokines may contribute to the pathogenesis of myxomatosis in European rabbits. 
We examined the hypothesis that varied levels of PKR activation can influence NF-κB activity 
in transfected HeLa cells. To test this hypothesis, we used an NF-κB activity reporter, designated 
NF-κB-luc, in which a firefly luciferase coding cassette is driven by multiple NF-κB binding 
motifs. The firefly luciferase activity can thus be used as a proxy for NF-κB activity. We co-
transfected HeLa-PKRkd cells with plasmids encoding European or brush rabbit PKR, NF-κB-luc 
and M156R as well as a plasmid encoding for a TK promoter-driven renilla luciferase as internal 
controls. The internally controlled luciferase activities (firefly luciferase light units /renilla 
luciferase light units) were normalized to that of PKR-only transfected cells to obtain relative 
luciferase activity as shown in our results. We first observed that the co-transfection of M156R 
and European rabbit PKR resulted in an approximately 4.5-fold increase of luciferase activity 
compared to that of European rabbit PKR-only transfected cells (Fig. 4.13 A). In contrast, co-
transfection of M156R with brush rabbit PKR failed to increase, but instead led to a slight 
decrease in luciferase activity (Fig. 4.13 A), indicating that NF-κB activity was not induced 
when brush rabbit PKR was fully inhibited by M156R, but only when PKR was moderately 
inhibited, demonstrated by the inhibition of European rabbit PKR by M156R. We next 
performed a control experiment where a similar dual-luciferase transfection was conducted in 
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which the NF-κB-luc was replaced by an SV40 promoter-driven firefly luciferase (SV40-luc). 
The luciferase activity restored by M156R co-transfection was slightly higher in brush rabbit 
PKR-transfected cells than European rabbit PKR-transfected cells but the difference was not 
statistically significant (P>0.05) (Fig. 4.13 B), indicating the difference we observed in the NF-
κB reporter assay could be attributed to different levels of NF-κB activity. Overall, these results 
indicate that NF-κB activity in cells can be influenced by the extent of PKR inhibition by 
M156R, and that intermediate PKR inhibition stimulates higher level of NF-kB activation than 
that when PKR is not inhibited or completely inhibited. 
We next tested if mutations on the helix αG region of European and brush rabbit PKR, 
which exchanged PKR sensitivities to M156R inhibition, could also alter NF-κB activity in 
transfected HeLa cells. For an easier comparison, we set the internally controlled firefly 
luciferase activity (as a readout of NF-κB activity) from cells co-transfected with European 
rabbit PKR and M156R as 100%. Similar to what we observed previously, co-transfection of 
M156R with brush rabbit PKR, caused reduced NF-kB activity compared to that with European 
rabbit PKR (~70% reduction) (Fig. 4.14). However, the mutation of European rabbit PKR with 
the helix αG region from brush rabbit PKR led to reduced NF-κB activity comparable to levels 
observed when brush rabbit PKR was co-transfected with M156R. Moreover, the NF-κB activity 
induced by co-transfection of the brush rabbit PKR mutant and M156R was augmented greatly 
when the helix αG from European rabbit PKR was introduced (Fig. 4.14). These observations 
confirm that the cellular NF-κB activity level rises only when PKR is moderately inhibited but 
not when completely inhibited by M156R. 
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We have concluded that M156R did not evolve to most efficiently to inhibit European 
rabbit PKR, causing an intermediate level of inhibition, which resulted in high NF-κB activation. 
Because of this we surmised that mutants of M156R might be identified who show stronger 
inhibition of European rabbit PKR. To identify such gain-of-function mutants, we screened a 
library of randomly mutated M156R for increased PKR inhibitory capabilities. We engineered a 
yeast strain that possesses chromosomally integrated European rabbit PKR (J986) and randomly 
mutagenized M156R by PCR with a low-fidelity polymerase. The J986 strain was then 
transformed with the mutagenized library and 4,000 clones were picked and analyzed in a yeast 
growth assay. Plasmids were isolated from clones that showed better growth than the wild type 
M156R transformant, amplified and re-transformed into the J986 strain for confirmation. 
Candidates were also subjected to the luciferase assay described in the previous section for 
confirmation, because this is more sensitive than the yeast growth assay, for confirmation. Four 
mutations (K48Q, E55V, N66D and Q69L) were identified that all exhibited more efficient PKR 
inhibition than the wild type M156R. Among them, M156R-K48Q significantly increased its 
inhibition of European rabbit PKR in the luciferase assay, but interestingly, this mutation did not 
influence the inhibition of brush rabbit PKR (Fig. 4.15 A). We also verified that the increased 
PKR inhibitory ability of M156R-K48Q was not due to over-expression of the protein by 
Western blot analysis (Fig. 4.15 B). These results show that M156R could be optimized to better 
inhibit European rabbit PKR and identified residue K48 as being important for its interaction 
with PKR.  
We next examined if increased PKR inhibition by M156R-K48Q could alter the NF-κB 
activation mediated by PKR and found that co-transfection of European rabbit PKR with 
M156R-K48Q resulted in a 70% reduction of NF-κB activity compared to that in cells co-
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transfected with European rabbit PKR and the wild type M156R (Fig. 4.16). This result confirms 
our hypothesis that the degree of PKR inhibition by M156R is directly correlated with NF-κB 
activation mediated by PKR. 
All these results indicate that intermediate inhibition of European rabbit PKR by M156R 
led to higher NF-κB activity in transfected HeLa cells than the strong inhibition of brush rabbit 
PKR by M156R. This difference may constitute a molecular mechanism which explains the 
virulence difference of MYXV observed in European and brush rabbits.  
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Discussion 
MYXV is a rabbit-specific pathogen that naturally infects Sylvilagus rabbit species. We 
previously showed that the MYXV PKR pseudosubstrate inhibitor M156R selectively inhibited 
only rabbit PKR, but not PKR from other mammalian species, which constitutes a molecular 
explanation for the restriction of MYXV infection to rabbits. The previous study was performed 
with PKR derived from European rabbits (Oryctolagus cuniculus), the most commonly used 
species for rabbit models in laboratories. European rabbits are intermediately related to 
American Sylvilagus rabbits, but they are not natural host of MYXV and have never naturally 
encountered MYXV in its evolutionary history before the very deliberate release of the virus in 
Australia and Europe in the 1950s. In research focused on virus-host interactions between 
MYXV and rabbits, European rabbits, but not brush rabbits are often used. In fact, the majority 
of research in the area of host-pathogen interactions with MYXV has been performed with New 
Zealand White rabbits, which is an European rabbit strain, with European rabbit-derived cells 
lines or cell lines derived from non-rabbit species.  
Like all poxviruses, MYXV possesses a large arsenal of immunomodulatory genes, that 
evolved to specifically antagonize one or multiple pathways in the hosts’ antiviral immune 
systems to facilitate viral replication (25). The immunomodulatory genes from MYXV all 
evolved in its natural host Sylvilagus rabbits, including tapeti rabbits and brush rabbits. The 
differential PKR sensitivity to M156R inhibition between European rabbit and brush rabbit 
demonstrated here, indicates that the host-virus interactions can be very distinct even between 
closely related species such as European rabbits and brush rabbits. Ideally, studies of host-virus 
interactions should be conducted in biologically relevant species, otherwise, the conclusions 
could be misleading or incomplete.  
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An even more dramatic example of species-specific PKR inhibition was revealed by the 
selective inhibition of brush rabbit PKR by the RFV K3L orthologs, R156R. RFV naturally 
infects Eastern cottontails (Sylvilagus floridanus), which are closely related to the brush rabbits 
(Sylvilagus bachmani). Unlike MYXV, which also evolved in Sylvilagus rabbits, RFV displays 
low virulence in European rabbits and provides heterologous protection in European rabbits for 
MYXV infection. R156R shows 77% sequence identity with M156R at the protein level, and 
could inhibit brush rabbit PKR as efficiently as M156R at various concentrations. However, 
R156R completely failed to inhibit European rabbit PKR. The inability of R156R to inhibit 
European rabbit PKR could contribute to the lower virulence of RFV in European rabbits 
compared to that of MYXV. 
The helix αG region on PKR constitutes the principal binding sites for eIF2α, making it 
also the likely target of poxvirus K3L orthologs, which compete with eIF2α for PKR binding. A 
selection analysis covering PKR from twelve different rodent and rabbit species revealed that 
three out of the four residue positions that differ between European and brush rabbit PKR are 
also under strong positive selective pressure in rodent species (Sherry Haller, personal 
communication). Our experiments with PKR mutants demonstrate that the swapping of the three 
residues (V485, A488 and A492 in European rabbit PKR and the corresponding residues in 
brush rabbit PKR) can exchange their sensitivities to M156R and R156R, without compromising 
their catalytic activity. This suggests that the selective pressure placed on the helix αG region 
was partly due to interactions with viral pseudosubstrate inhibitors. Mutations that exchange the 
residue 496 and its corresponding residue on brush rabbit PKR, which is not under positive 
selective pressure, did not change PKR sensitivity to M156R or R156R.  
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PKR contributes to many different aspects of antiviral immune responses in vertebrates. 
In addition to its roles as both a virus sensor and an antiviral effector, PKR is also shown to 
contribute to the activation of NF-κB, a transcription factor that orchestrates pro-inflammatory 
responses in response to virus infection. It has been shown that catalytically active PKR is 
required for NF-κB induction during poxvirus infection (26). Under normal condition, NF-κB is 
sequestered in the cytoplasm by a family of NF-κB inhibitors called IκB. During virus infection, 
the expression of IκB and NF-κB are both inhibited due to PKR-mediated translational 
suppression. However, IκB degrades more rapidly than NF-κB due to its shorter half-life. As a 
result, free NF-κB can translocate to the nucleus and becomes active. Activation of NF-κB leads 
to induction of cytokines such as interleukin-1, interleukin-6 and tumor necrosis factor-α, which 
are collectively named pro-inflammatory cytokines, which promote inflammation (reviewed in 
(23)). Severe inflammatory responses, such as swellings of the ears, eyelids, scrotums and 
genital areas, are signature symptoms of myxomatosis in European rabbits (27). We thus 
speculate that the balance between PKR activation and inhibition may contribute to the 
pathogenesis of myxomatosis by regulating NF-κB activity. A possible explanation for the 
correlation between PKR activity and NF-κB activation is summarized in Fig. 4.17. When PKR 
is completely inhibited by viral inhibitors (scenario A), the NF-κB pathway is not activated 
because the continuous production of IκB is not prohibited. When PKR is not being inhibited, or 
PKR is completely resistant to viral inhibition (scenario B), the NF-κB pathway is readily 
activated, resulting in transcriptional upregulation of pro-inflammatory cytokines. However, due 
to the strong global translational suppression mediated by PKR, translation of the cytokine 
transcripts (or firefly luciferase assay in our assay) are prevented. When PKR is moderately 
inhibited (scenario C), the intermediate activity levels of PKR trigger activation of the NF-κB 
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pathway, which induces the transcription of pro-inflammatory cytokines. Meanwhile, the 
transcripts are able to be translated due to incomplete shut down of translation by the partially 
inhibited PKR. These scenarios correlate with the differential NF-κB activity we observed in our 
experimental settings and might contribute to the dramatic difference in pathology of MYXV 
infection in different rabbit species. However, it is worth noting that further experiments are 
required to directly monitor the levels of NF-κB-induced transcripts under all three scenarios and 
to perform infection experiments in rabbits to corroborate our hypothesis.  
We discovered that NF-κB-regulated luciferase expression is tightly associated with the 
degree of PKR activity, and demonstrate that intermediate inhibition of European rabbit PKR 
could result in the elevated expression of NF-κB-inducible proteins compared to when PKR is 
completely inhibited such as with brush rabbit PKR by M156R. One possible explanation is that 
MYXV M156R evolved to optimally inhibit brush rabbit PKR, and by chance making it a less 
efficient inhibitor of European rabbit PKR.  
Overall, our results suggest that viral immunomodulatory proteins that evolved in one 
host species may display different levels of immunomodulation in another host species, as 
exemplified by the inability of RFV R156R to inhibit European rabbit PKR, or the reduced 
inhibition of European rabbit PKR by MYXV M156R. However, such differences might have 
been overlooked in the past, because most MYXV immunomodulatory proteins are characterized 
in European rabbits, European rabbit-derived cells lines or even cells from non-rabbit mammals. 
We demonstrated here that it is important to study virus host range and virulence factors in 
biologically relevant species.  
  
149 
 
 
 
 
Figure 4.1 Comparison of PKR from different rabbit species 
 
Sequences alignment was performed using the program MUSCLE (url: 
http://www.ebi.ac.uk/Tools/msa/muscle). Abbreviations: oc: Oryctolagus cuniculus, European 
rabbit; sb: Sylvilagus bachmani, brush rabbit. 
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Figure 4.2 Inhibition of rabbit PKR by MYXV M156R 
 
Human HeLa-PKRkd cells were transfected with expression vectors for luciferase 
(0.05µg), MYXV Lu-M156R (0.4µg) and PKR (0.2µg) from the indicated species. Luciferase 
light units were normalized to PKR-only transfected cells to obtain relative luciferase activities. 
Experiments were performed in triplicate and the results are representative of three independent 
experiments. Error bars indicate standard deviations. P values were calculated by the Student’s 
T-test.  
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Figure 4.3 Inhibition of rabbit PKR by VACV K3L 
 
Human HeLa-PKRkd cells were transfected with expression vectors for luciferase 
(0.05µg), VACV K3L (0.4µg) and PKR (0.2µg) from the indicated species. Luciferase light units 
were normalized to PKR-only transfected cells to obtain relative luciferase activities. 
Experiments were performed in triplicate and the results are representative of three independent 
experiments. Error bars indicate standard deviations. P values were calculated by the Student’s 
T-test.  
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Figure 4.4 Expression of rabbit PKR in HeLa cells 
 
HeLa-PKRkd cells were transfected with 3µg of vector, FLAG-tagged European rabbit 
PKR or brush rabbit PKR plasmids. Total protein was collected 48 hours after transfection with 
1%-SDS. All protein samples were separated by SDS-PAGE and subjected to Western blotting 
analyses. The membrane was first probed with an anti-FLAG antibody, then consecutively 
stripped and re-probed for β-actin (loading control).  
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Figure 4.5 Quantification of eIF2α phosphorylation in PKR-transfected HeLa cells 
 
HeLa-PKRkd cells were transfected with expression vectors for ATF4-firefly luciferase 
(0.05µg) which contains the mouse ATF4 mRNA-5’UTR sequence (20), TK-renilla luciferase 
(0.05µg) driven by the TK promoter, VACV K3L (0.4µg), MYXV M156R (0.4µg), European 
rabbit PKR (0.2µg) or brush rabbit PKR (0.2µg). Luciferase activities were measured after 48 
hours and was internally controlled by normalizing light units produced by firefly luciferase to 
that produced by renilla luciferase. Values obtained were then further normalized to PKR-only 
transfected cells to calculate relative luciferase activity. Error bars indicate standard deviation. P 
values were calculated by the Student’s T-test.  
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Figure 4.6 Inhibition of rabbit PKR by M156R from two different MYXV strains 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), MYXV Lu-M156R (0.4µg) or MSW-M156R and PKR (0.2µg) from the indicated 
species. Luciferase light units were normalized to PKR-only transfected cells to obtain relative 
luciferase activities. Experiments were performed in triplicate and the results are representative 
of three independent experiments. Error bars indicate standard deviations. P values were 
calculated by the Student’s T-test.  
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Figure 4.7 Inhibition of rabbit PKR by M156R and R156R 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), Lu-MYXV M156R or RFV R156R (0.4µg) as well as PKR (0.2µg) from the indicated 
species. Luciferase light units were normalized to PKR-only transfected cells to obtain relative 
luciferase activities. Experiments were performed in triplicate and the results are representative 
of three independent experiments. Error bars indicate standard deviations and P values were 
calculated by the Student’s T-test. 
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Figure 4.8 Expression of M156R and R156R in HeLa cells 
 
 
HeLa-PKRkd cells were transfected with 3µg of M156R or R156R encoding plasmids. 
Total proteins was collected 48 hours after transfection with 1%-SDS. All protein samples were 
separated on SDS-PAGE and subjected to Western blotting analyses. The membrane was first 
probed with an anti-FLAG antibody, then consecutively stripped and probed for β-actin (loading 
control). 
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Figure 4.9 Quadruple mutation in the helix αG region altered PKR sensitivity to MYXV 
M156R and R156R 
 
(A) The kinase domain of human PKR. The corresponding residues in European and 
brush rabbit PKRs are labeled according to European rabbit PKR. Blue: residues directly contact 
eIF2α. Red: residues that are different between European rabbit and brush rabbit PKR. The four 
residues that differ between European and brush rabbit PKR in the helix αG region are labeled 
with yellow lines. (B)Human HeLa-PKRkd cells were transfected with expression vectors for 
firefly luciferase (0.05µg), MYXV M156R or RFV R156R (0.4µg), and PKR or PKR mutants 
(0.2µg) from the indicated species. Experiments were performed in triplicate and the results are 
representative of three independent experiments. Error bars indicate standard deviations.   
158 
 
 
 
 
Figure 4.10 Effects of the single mutations in the helix αG region on PKR sensitivity to 
M156R and R156R 
 
 
Single amino-acid mutations in the helix αG region of European or brush rabbit PKR 
were tested in the luciferase assay described previously and the results are summarized here. 
Amino acid residues are numbered according to their positions in European rabbit PKR. 
Abbreviations: E=European rabbit, b=brush rabbit. 
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Figure 4.11 Triple mutations in the helix αG region altered PKR sensitivity to M156R 
inhibition 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), MYXV M156R as well as PKR and PKR mutants (0.2µg) from the indicated species. 
Luciferase light units were normalized to PKR-only transfected cells to obtain relative luciferase 
activities. Experiments were performed in triplicate and the results are representative of three 
independent experiments. Error bars indicate standard deviations.  
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Figure 4.12 Triple mutations in the helix αG region altered PKR sensitivity to R156R 
inhibition 
 
Human HeLa-PKRkd cells were transfected with expression vectors for firefly luciferase 
(0.05µg), RFV R156R as well as PKR and PKR mutants (0.2µg) from the indicated species. 
Luciferase light units were normalized to PKR-only transfected cells to obtain relative luciferase 
activities. Experiments were performed in triplicate and the results are representative of three 
independent experiments. Error bars indicate standard deviations.  
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Figure 4.13 Moderate inhibition of PKR resulted in NF-κB activation 
 
HeLa-PKRkd cells were transfected with TK-renilla luciferase (0.05µg), NF-κB-luc 
(0.05µg) (A) or SV40-luc (0.05µg) (B), MYXV M156R (0.4µg) and PKR (0.2µg) plasmids from 
indicated rabbit species. Light units for firefly and renilla luciferase were measured with the 
Dual-glo detection kit (Promega) 48 hours after transfection. Results from the firefly luciferase 
were normalized to renilla luciferase results in the same well to obtain internally controlled 
luciferase activity. The values were further normalized to PKR-only transfected cells to obtain 
relative luciferase activities. Error bars indicate standard deviation. P values were calculated by 
the Student’s T-test.  
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Figure 4.14 Intermediate PKR sensitivity to M156R resulted in NF-κB activation 
 
HeLa-PKRkd cells were transfected with TK-renilla luciferase (0.05µg), NF-κB-luc 
(0.05µg), MYXV M156R (0.4µg) as well as European rabbit PKR, brush rabbit PKR and their 
mutants indicated in the figure (0.2µg). Light units for firefly and renilla luciferase were 
measured with the Dual-glo detection kit (Promega) 48 hours after transfection. Results from the 
firefly luciferase were normalized to results from the renilla luciferase in the same well to obtain 
internally controlled luciferase activity. The values were further normalized to PKR-only 
transfected cells to obtain relative luciferase activities. Error bars indicate standard deviation. P 
values were calculated by the Student’s T-test. 
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Figure 4.15 M156R-K48Q is a hyperactive inhibitor of European rabbit PKR 
 
(A) Human HeLa-PKRkd cells were transfected with expression vectors for firefly 
luciferase (0.05µg), MYXV M156R or M156R-K48Q (0.4µg) as well as PKR (0.2µg) from the 
indicated species. Luciferase light units were normalized to PKR-only transfected cells to obtain 
relative luciferase activities. Experiments were performed in triplicate and the results are 
representative of three independent experiments. Error bars indicate standard deviations. P 
values were calculated with the Student’s T-test. (B) HeLa-PKRkd cells were transfected with 
3µg of vector, M156R or M156R-K48Q plasmids. Total protein was collected 48 hours after 
transfection and separated by SDS-PAGE for Western blotting analysis. The membrane was first 
probed with anti-M156 antiserum and then stripped and reprobed with anti-β-actin antibody 
(loading control)  
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Figure 4.16 Enhanced inhibition of European rabbit PKR resulted in reduced 
 
HeLa-PKRkd cells were transfected with TK-renilla luciferase (0.05µg), NF-κB-luc 
(0.05µg), MYXV M156R or M156R-K48Q (0.4µg) as well as European rabbit PKR (0.2µg). 
Light units for firefly and renilla luciferase were measured with the Dual-glo detection kit 
(Promega) 48 hours after transfection. Results from the firefly luciferase were normalized to 
renilla luciferase results in the same well to obtain internally controlled luciferase activity. The 
values were further normalized to PKR-only transfected cells to obtain relative luciferase 
activities. Error bars indicate standard deviation. P values were calculated by the Student’s T-
test.  
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Figure 4.17 Hypothetical correlation between PKR activity and the expression of NF-κB-
regulated pro-inflammatory cytokines 
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Chapter 5 - Conclusion 
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The research presented in this dissertation reveals that inhibition of the host antiviral 
protein kinase R (PKR) by poxvirus pseudosubstrate inhibitors is species-specific. Furthermore, 
we noticed that myxoma virus and swinepox virus K3L orthologs inhibit PKR from the natural 
hosts of the viruses with highest efficiency, which may explain why infections of these two 
viruses are restricted to only certain host species. We also observed that PKR from even very 
closely related species, such as European rabbit and brush rabbit, show differential sensitivities 
to myxoma virus M156 inhibition, and most importantly, we unveil a possible mechanism by 
which moderate PKR activity triggers robust induction of NF-κB-regulated protein expression, 
which may contribute to the pathogenesis of myxomatosis. Overall, our findings suggest that the 
species-specific interactions between PKR and its viral antagonists is a critical factor that 
influences poxvirus replication and host range.  
Through a combination of molecular, biological and biochemical approaches, we 
demonstrated that myxoma virus M156R specifically inhibited only rabbit PKR, but not human 
PKR and PKR from other mammalian species tested. We also showed that M156R-L98P, a 
mutant that arose from a single nucleotide mutation in M156R found in more than 50% field 
isolates lost its PKR inhibitory ability. This finding reveals a possible mechanism for the 
attenuation of the myxoma virus in Australia after its repeated release.   
We next thoroughly examined the differences between European rabbit and its close 
relative, the brush rabbit, in terms of PKR sensitivity to M156R inhibition and find that brush 
rabbit PKR was better inhibited by M156R than European rabbit PKR. This difference in PKR 
sensitivity is intriguing, considering the dramatically distinctive evolutionary history of myxoma 
virus in these two rabbit species. Whereas myxoma virus has been evolving in American 
Sylvilagus rabbits, European rabbit population in the wild have never naturally encountered the 
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virus before the 1950’s. The difference we observed in PKR sensitivity between European rabbit 
and brush rabbit to M156R inhibition suggests that myxoma virus M156R evolved to inhibit 
PKR from its natural host with highest efficiency. Generally, in the co-evolution of any virus-
host pair, it is acknowledged that the effects of evolution on the fitness of the virus and the host 
act in opposite directions: the evolutionary advantages gained by the virus are bad for the host 
and vice versa. However, the data described in this dissertation demonstrate that even though the 
long-term adaptation of myxoma virus to its natural host Sylvilagus rabbit resulted in the 
optimization of M156R to completely inhibit this species’ PKR, this “advantage” obtained 
through evolution for the virus does not necessarily lead to increased virulence that directly 
reduces the host fitness. In contrast, we show in our NF-κB reporter assays that the stronger 
inhibition of brush rabbit PKR by M156R surprisingly led to the reduced activity of a pro-
inflammatory transcription factor NF-κB, in contrast to the higher NF-κB resulting from the 
moderate inhibition of European rabbit PKR. This difference correlates with the virulence 
difference of myxoma virus in these two rabbit species. Therefore, we propose that stronger 
inhibition of PKR, as the result of extensive virus-host co-evolution, does not lead to higher 
virulence, but instead decreases its virulence, which increases the fitness of both the host and the 
virus. However, whether NF-κB activity directly contributes to the pathogenesis of myxomatosis 
still requires further investigation. 
By combining a selection analysis and molecular biology techniques, we successfully 
pin-pointed the residues on rabbit PKRs that are responsible for their differential sensitivity to 
pseudosubstrate inhibitors from myxoma and rabbit fibroma viruses. We discovered that 
mutations of residues that differ between European rabbit PKR and brush rabbit PKR, which are 
also under strong positive selective pressure, altered PKR sensitivities to M156R and R156R. 
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This indicates that the selective pressure exerted by viral antagonists on PKR is a major driving 
force for the rapid evolution of this antiviral protein. While PKR is constantly evolving to evade 
viral inhibition, viral inhibitors are also evolving quickly to re-establish effective PKR inhibition 
to allow virus replication. The ongoing arms-race between the host and the virus drives the fast 
evolution of both PKR and its viral antagonists.  
Emerging and re-emerging infectious diseases including Ebola, SARS, influenza and 
monkeypox remain a major threat to human health because the host range of each virus and the 
likelihood of cross-species transmission is unpredictable based on current knowledge. Through 
the study of interactions between vaccinia virus K3L and PKR from multiple species, we learned 
that PKR from different species are inhibited differentially by a given viral antagonist, and that 
these differences play a role in determining virus replication and suppression of the host’s 
immune response during infection. Information like these is valuable because it might help us to 
better predict the virulence and host range of newly emerging and re-emerging viral pathogens.  
 
